Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Editorial Policies | 114 | 2017 | 458 | 11.720 |
Why?
|
Periodicals as Topic | 116 | 2022 | 1462 | 8.150 |
Why?
|
Conflict of Interest | 41 | 2015 | 556 | 6.370 |
Why?
|
Disclosure | 27 | 2015 | 756 | 5.460 |
Why?
|
Asthma | 165 | 2024 | 6270 | 5.330 |
Why?
|
Clinical Trials as Topic | 103 | 2020 | 8041 | 3.690 |
Why?
|
Anti-Asthmatic Agents | 32 | 2023 | 572 | 3.550 |
Why?
|
Information Dissemination | 34 | 2020 | 1142 | 3.280 |
Why?
|
Leukotriene Antagonists | 20 | 2011 | 124 | 2.790 |
Why?
|
Bronchi | 66 | 2020 | 843 | 2.670 |
Why?
|
Bronchoconstriction | 23 | 2024 | 141 | 2.520 |
Why?
|
Government Regulation | 12 | 2019 | 525 | 2.210 |
Why?
|
Supreme Court Decisions | 11 | 2015 | 135 | 2.100 |
Why?
|
Research Support as Topic | 30 | 2020 | 696 | 2.030 |
Why?
|
Leukotrienes | 25 | 2011 | 232 | 1.940 |
Why?
|
Firearms | 10 | 2017 | 630 | 1.880 |
Why?
|
Publishing | 30 | 2016 | 835 | 1.810 |
Why?
|
Lung | 107 | 2023 | 10033 | 1.730 |
Why?
|
United States Food and Drug Administration | 17 | 2019 | 1672 | 1.720 |
Why?
|
Arachidonate 5-Lipoxygenase | 15 | 2009 | 128 | 1.710 |
Why?
|
Histamine | 59 | 1997 | 497 | 1.700 |
Why?
|
Airway Resistance | 58 | 2004 | 407 | 1.650 |
Why?
|
Adrenergic beta-Agonists | 21 | 2011 | 345 | 1.620 |
Why?
|
SRS-A | 37 | 2003 | 132 | 1.610 |
Why?
|
Clinical Medicine | 3 | 2023 | 145 | 1.570 |
Why?
|
Bronchodilator Agents | 18 | 2018 | 514 | 1.570 |
Why?
|
Lipoxygenase Inhibitors | 16 | 2002 | 93 | 1.540 |
Why?
|
Oxygen Inhalation Therapy | 4 | 2024 | 418 | 1.480 |
Why?
|
Registries | 51 | 2017 | 8297 | 1.320 |
Why?
|
Nitric Oxide Synthase | 19 | 2004 | 911 | 1.270 |
Why?
|
Drug Industry | 20 | 2015 | 791 | 1.260 |
Why?
|
Peer Review, Research | 19 | 2014 | 341 | 1.260 |
Why?
|
Substance P | 18 | 1995 | 331 | 1.250 |
Why?
|
Bronchial Hyperreactivity | 20 | 2011 | 300 | 1.210 |
Why?
|
Politics | 10 | 2017 | 822 | 1.200 |
Why?
|
Civil Rights | 5 | 2016 | 129 | 1.200 |
Why?
|
Embryo Research | 4 | 2015 | 38 | 1.180 |
Why?
|
Abortion, Legal | 4 | 2015 | 121 | 1.160 |
Why?
|
International Cooperation | 30 | 2017 | 1432 | 1.060 |
Why?
|
Hydroxyurea | 13 | 2001 | 284 | 1.040 |
Why?
|
Informed Consent | 5 | 2015 | 1010 | 1.040 |
Why?
|
Trachea | 38 | 2011 | 1085 | 1.030 |
Why?
|
Glucocorticoids | 13 | 2012 | 2132 | 1.020 |
Why?
|
Receptors, Leukotriene | 13 | 2011 | 97 | 1.010 |
Why?
|
Internet | 10 | 2018 | 3106 | 1.000 |
Why?
|
Hemorrhagic Fever, Ebola | 3 | 2014 | 424 | 0.970 |
Why?
|
Guinea Pigs | 75 | 2002 | 1300 | 0.970 |
Why?
|
Respiration | 38 | 2002 | 1653 | 0.950 |
Why?
|
Clinical Trials Data Monitoring Committees | 2 | 2018 | 25 | 0.950 |
Why?
|
United States Public Health Service | 2 | 2014 | 31 | 0.920 |
Why?
|
National Institutes of Health (U.S.) | 6 | 2020 | 791 | 0.920 |
Why?
|
Nitric Oxide | 20 | 2004 | 2143 | 0.920 |
Why?
|
Albuterol | 18 | 2010 | 211 | 0.910 |
Why?
|
Epithelial Cells | 18 | 2024 | 3681 | 0.900 |
Why?
|
Violence | 4 | 2016 | 935 | 0.900 |
Why?
|
Confidentiality | 7 | 2016 | 607 | 0.870 |
Why?
|
Academic Medical Centers | 5 | 2015 | 2780 | 0.860 |
Why?
|
Azetidines | 3 | 2010 | 150 | 0.860 |
Why?
|
Humans | 404 | 2024 | 765956 | 0.820 |
Why?
|
Mechanotransduction, Cellular | 4 | 2015 | 540 | 0.810 |
Why?
|
United States | 78 | 2020 | 72898 | 0.800 |
Why?
|
Taxes | 3 | 2017 | 219 | 0.800 |
Why?
|
Respiratory System | 19 | 2024 | 559 | 0.790 |
Why?
|
Stress, Mechanical | 11 | 2020 | 1669 | 0.780 |
Why?
|
Tosyl Compounds | 8 | 2002 | 115 | 0.770 |
Why?
|
Simvastatin | 4 | 2014 | 345 | 0.760 |
Why?
|
Artificial Intelligence | 4 | 2024 | 2659 | 0.760 |
Why?
|
Authorship | 18 | 2013 | 288 | 0.750 |
Why?
|
Respiratory Mucosa | 7 | 2015 | 438 | 0.740 |
Why?
|
State Government | 6 | 2016 | 388 | 0.730 |
Why?
|
ADAM Proteins | 3 | 2013 | 242 | 0.730 |
Why?
|
Colonic Neoplasms | 3 | 2018 | 2531 | 0.710 |
Why?
|
Administration, Inhalation | 26 | 2023 | 1154 | 0.700 |
Why?
|
Gambling | 1 | 2023 | 180 | 0.700 |
Why?
|
Airway Remodeling | 3 | 2020 | 134 | 0.700 |
Why?
|
Respiratory Physiological Phenomena | 9 | 2006 | 190 | 0.690 |
Why?
|
Education, Medical, Continuing | 2 | 2019 | 830 | 0.670 |
Why?
|
Churg-Strauss Syndrome | 5 | 2000 | 74 | 0.670 |
Why?
|
Pharmacies | 2 | 2012 | 171 | 0.670 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 8 | 2024 | 3247 | 0.660 |
Why?
|
Interprofessional Relations | 2 | 2016 | 999 | 0.660 |
Why?
|
Neurokinin A | 11 | 1994 | 32 | 0.660 |
Why?
|
Drug Approval | 7 | 2011 | 818 | 0.650 |
Why?
|
Device Approval | 4 | 2009 | 164 | 0.650 |
Why?
|
Human Experimentation | 2 | 2013 | 124 | 0.650 |
Why?
|
Oxygen | 15 | 2024 | 4241 | 0.650 |
Why?
|
Lactones | 3 | 2006 | 316 | 0.640 |
Why?
|
Muscle, Smooth | 29 | 2002 | 931 | 0.640 |
Why?
|
Wounds, Gunshot | 6 | 2017 | 585 | 0.640 |
Why?
|
Sulfones | 3 | 2006 | 447 | 0.630 |
Why?
|
Bronchitis | 10 | 2002 | 193 | 0.630 |
Why?
|
Epidemics | 2 | 2014 | 514 | 0.620 |
Why?
|
Biomedical Research | 21 | 2022 | 3458 | 0.620 |
Why?
|
Flavoring Agents | 1 | 2019 | 54 | 0.610 |
Why?
|
Organizational Policy | 4 | 2014 | 434 | 0.600 |
Why?
|
Mass Casualty Incidents | 2 | 2017 | 178 | 0.600 |
Why?
|
Liability, Legal | 3 | 2009 | 209 | 0.600 |
Why?
|
High-Frequency Ventilation | 2 | 2013 | 90 | 0.590 |
Why?
|
Gene Expression | 9 | 2020 | 7584 | 0.590 |
Why?
|
Severe Acute Respiratory Syndrome | 3 | 2003 | 136 | 0.590 |
Why?
|
Anticholesteremic Agents | 3 | 2010 | 970 | 0.570 |
Why?
|
Legislation, Drug | 3 | 2009 | 217 | 0.560 |
Why?
|
Adrenergic beta-2 Receptor Agonists | 1 | 2018 | 109 | 0.560 |
Why?
|
Methacholine Chloride | 21 | 2011 | 220 | 0.550 |
Why?
|
Advisory Committees | 7 | 2016 | 796 | 0.540 |
Why?
|
Administrative Personnel | 2 | 2015 | 186 | 0.540 |
Why?
|
Homeodomain Proteins | 2 | 2016 | 2428 | 0.530 |
Why?
|
Certification | 2 | 2010 | 416 | 0.530 |
Why?
|
Abortifacient Agents, Steroidal | 1 | 2016 | 22 | 0.530 |
Why?
|
Physician-Patient Relations | 4 | 2017 | 3278 | 0.520 |
Why?
|
Neprilysin | 13 | 1995 | 484 | 0.520 |
Why?
|
Forced Expiratory Volume | 30 | 2004 | 1828 | 0.510 |
Why?
|
Medicine | 3 | 2023 | 942 | 0.510 |
Why?
|
Sulfonamides | 10 | 2014 | 1984 | 0.510 |
Why?
|
Adrenal Cortex Hormones | 16 | 2023 | 1880 | 0.510 |
Why?
|
Immunoglobulin E | 17 | 2005 | 1481 | 0.510 |
Why?
|
Insurance, Health | 4 | 2017 | 2520 | 0.500 |
Why?
|
Physician's Role | 2 | 2016 | 927 | 0.500 |
Why?
|
Voluntary Health Agencies | 1 | 2015 | 38 | 0.500 |
Why?
|
Thiazolidinediones | 2 | 2010 | 459 | 0.500 |
Why?
|
Drug Labeling | 2 | 2016 | 250 | 0.490 |
Why?
|
Dogs | 46 | 1993 | 3822 | 0.490 |
Why?
|
Mifepristone | 1 | 2016 | 150 | 0.490 |
Why?
|
Vasoactive Intestinal Peptide | 6 | 1995 | 179 | 0.490 |
Why?
|
Attitude to Death | 1 | 2018 | 399 | 0.480 |
Why?
|
Leukotriene E4 | 13 | 2000 | 75 | 0.480 |
Why?
|
Eosinophils | 12 | 2003 | 945 | 0.480 |
Why?
|
Tidal Volume | 19 | 2002 | 519 | 0.480 |
Why?
|
Job Description | 1 | 2014 | 61 | 0.470 |
Why?
|
Bibliometrics | 2 | 2015 | 357 | 0.460 |
Why?
|
Receptors, Adrenergic, beta-2 | 11 | 2004 | 216 | 0.460 |
Why?
|
Acetates | 5 | 2010 | 313 | 0.460 |
Why?
|
Internal Medicine | 3 | 2010 | 1064 | 0.450 |
Why?
|
Mast Cells | 12 | 2011 | 1412 | 0.450 |
Why?
|
Immediate-Early Proteins | 4 | 2001 | 444 | 0.450 |
Why?
|
Capsaicin | 7 | 1995 | 226 | 0.440 |
Why?
|
Nebulizers and Vaporizers | 4 | 2023 | 138 | 0.430 |
Why?
|
Federal Government | 2 | 2013 | 265 | 0.430 |
Why?
|
Respiration, Artificial | 18 | 2003 | 2709 | 0.430 |
Why?
|
Lung Diseases | 7 | 2020 | 1940 | 0.430 |
Why?
|
Homosexuality, Female | 1 | 2015 | 171 | 0.420 |
Why?
|
Retinopathy of Prematurity | 2 | 2015 | 449 | 0.420 |
Why?
|
Marriage | 1 | 2015 | 351 | 0.420 |
Why?
|
Respiration Disorders | 2 | 2014 | 362 | 0.420 |
Why?
|
Tobacco Use Disorder | 1 | 2019 | 708 | 0.420 |
Why?
|
Access to Information | 2 | 2007 | 317 | 0.410 |
Why?
|
Polymorphism, Genetic | 18 | 2004 | 4247 | 0.410 |
Why?
|
Muscle Contraction | 30 | 2002 | 1206 | 0.410 |
Why?
|
Animals | 203 | 2015 | 168759 | 0.410 |
Why?
|
Goblet Cells | 2 | 2013 | 301 | 0.400 |
Why?
|
Education, Medical | 4 | 2022 | 1746 | 0.400 |
Why?
|
Lung Compliance | 31 | 1989 | 207 | 0.400 |
Why?
|
Epidermal Growth Factor | 4 | 2005 | 698 | 0.400 |
Why?
|
Health Personnel | 5 | 2017 | 3390 | 0.400 |
Why?
|
Drug Therapy, Combination | 13 | 2022 | 6309 | 0.400 |
Why?
|
Leukocyte Elastase | 1 | 2013 | 113 | 0.400 |
Why?
|
Fluorobenzenes | 1 | 2014 | 179 | 0.400 |
Why?
|
Quarantine | 1 | 2014 | 185 | 0.400 |
Why?
|
Pulmonary Gas Exchange | 11 | 2002 | 389 | 0.400 |
Why?
|
Uncertainty | 1 | 2017 | 761 | 0.400 |
Why?
|
Lung Volume Measurements | 17 | 2002 | 381 | 0.390 |
Why?
|
Teaching Rounds | 1 | 2016 | 280 | 0.390 |
Why?
|
New England | 5 | 2018 | 1059 | 0.390 |
Why?
|
Respiratory Function Tests | 23 | 2012 | 1693 | 0.390 |
Why?
|
Lung Diseases, Obstructive | 7 | 2000 | 309 | 0.390 |
Why?
|
Bronchial Spasm | 10 | 1989 | 71 | 0.390 |
Why?
|
Ebolavirus | 1 | 2014 | 250 | 0.390 |
Why?
|
Bronchoalveolar Lavage Fluid | 11 | 2012 | 755 | 0.380 |
Why?
|
Drug Compounding | 1 | 2012 | 235 | 0.380 |
Why?
|
Drug Evaluation | 2 | 2012 | 641 | 0.370 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 6 | 2005 | 2268 | 0.370 |
Why?
|
Genetic Testing | 2 | 2019 | 3595 | 0.370 |
Why?
|
State Health Plans | 2 | 2017 | 220 | 0.370 |
Why?
|
Specialty Boards | 2 | 2010 | 234 | 0.370 |
Why?
|
Cytokines | 17 | 2021 | 7421 | 0.370 |
Why?
|
Disease Outbreaks | 4 | 2009 | 1759 | 0.370 |
Why?
|
Randomized Controlled Trials as Topic | 10 | 2024 | 10383 | 0.360 |
Why?
|
Positive-Pressure Respiration | 3 | 2013 | 711 | 0.360 |
Why?
|
Receptors, Glucocorticoid | 2 | 2011 | 308 | 0.360 |
Why?
|
Equipment Safety | 2 | 2009 | 250 | 0.360 |
Why?
|
Scopolamine Derivatives | 1 | 2010 | 23 | 0.360 |
Why?
|
Chromosome Mapping | 8 | 2005 | 4618 | 0.360 |
Why?
|
Archives | 1 | 2010 | 15 | 0.360 |
Why?
|
Promoter Regions, Genetic | 11 | 2003 | 5786 | 0.350 |
Why?
|
Patient Rights | 2 | 2008 | 126 | 0.350 |
Why?
|
Prostaglandin-Endoperoxide Synthases | 4 | 2005 | 318 | 0.350 |
Why?
|
Health Care Reform | 3 | 2009 | 1259 | 0.350 |
Why?
|
Research Design | 7 | 2022 | 6208 | 0.350 |
Why?
|
Professional Role | 3 | 2017 | 313 | 0.350 |
Why?
|
Thromboplastin | 1 | 2012 | 289 | 0.350 |
Why?
|
Pulmonary Alveoli | 10 | 1997 | 664 | 0.350 |
Why?
|
Antihypertensive Agents | 2 | 2021 | 2033 | 0.350 |
Why?
|
Genome, Human | 6 | 2019 | 4448 | 0.350 |
Why?
|
Medical Records Systems, Computerized | 1 | 2016 | 1195 | 0.350 |
Why?
|
Cyclobutanes | 1 | 2010 | 57 | 0.340 |
Why?
|
Quinolines | 5 | 2010 | 769 | 0.340 |
Why?
|
Respiratory Hypersensitivity | 5 | 2002 | 271 | 0.340 |
Why?
|
Bronchial Provocation Tests | 15 | 2003 | 217 | 0.340 |
Why?
|
Appetite Depressants | 1 | 2010 | 108 | 0.340 |
Why?
|
Cyclooxygenase 2 Inhibitors | 3 | 2006 | 318 | 0.330 |
Why?
|
Bronchoconstrictor Agents | 6 | 2001 | 78 | 0.330 |
Why?
|
Phenylcarbamates | 8 | 2002 | 38 | 0.330 |
Why?
|
Infant, Premature, Diseases | 1 | 2015 | 713 | 0.330 |
Why?
|
Embryo, Mammalian | 3 | 2004 | 1673 | 0.330 |
Why?
|
Self-Help Groups | 1 | 2011 | 193 | 0.330 |
Why?
|
Interdisciplinary Communication | 2 | 2014 | 932 | 0.320 |
Why?
|
History, 20th Century | 7 | 2016 | 2761 | 0.320 |
Why?
|
History, 21st Century | 5 | 2016 | 1574 | 0.310 |
Why?
|
Cultural Diversity | 1 | 2013 | 370 | 0.310 |
Why?
|
Lymphangioleiomyomatosis | 1 | 2011 | 207 | 0.310 |
Why?
|
Biological Products | 1 | 2018 | 942 | 0.310 |
Why?
|
Legislation, Medical | 1 | 2009 | 99 | 0.310 |
Why?
|
Genomics | 2 | 2019 | 5929 | 0.300 |
Why?
|
Arachidonic Acids | 11 | 2004 | 293 | 0.300 |
Why?
|
Male | 182 | 2018 | 363691 | 0.300 |
Why?
|
Program Development | 1 | 2014 | 1295 | 0.300 |
Why?
|
Isoenzymes | 5 | 2002 | 1689 | 0.300 |
Why?
|
Drug and Narcotic Control | 1 | 2009 | 144 | 0.300 |
Why?
|
Vagus Nerve | 15 | 2002 | 460 | 0.300 |
Why?
|
Lipoxygenase | 3 | 1997 | 71 | 0.290 |
Why?
|
Contraceptives, Postcoital | 2 | 2005 | 15 | 0.290 |
Why?
|
Aprotinin | 2 | 2006 | 92 | 0.290 |
Why?
|
Capital Punishment | 1 | 2008 | 30 | 0.290 |
Why?
|
Research Personnel | 4 | 2016 | 590 | 0.290 |
Why?
|
Jurisprudence | 1 | 2008 | 109 | 0.290 |
Why?
|
Dose-Response Relationship, Drug | 50 | 2004 | 10729 | 0.290 |
Why?
|
Point-of-Care Systems | 1 | 2016 | 1217 | 0.290 |
Why?
|
Exosomes | 1 | 2012 | 421 | 0.290 |
Why?
|
Workload | 2 | 2004 | 851 | 0.290 |
Why?
|
Societies, Medical | 15 | 2017 | 3956 | 0.280 |
Why?
|
Death | 4 | 2020 | 686 | 0.280 |
Why?
|
Public Health | 5 | 2017 | 2680 | 0.280 |
Why?
|
Genetic Predisposition to Disease | 10 | 2019 | 18071 | 0.280 |
Why?
|
Databases as Topic | 2 | 2007 | 471 | 0.280 |
Why?
|
Universities | 1 | 2013 | 998 | 0.280 |
Why?
|
Tobacco Industry | 1 | 2008 | 138 | 0.280 |
Why?
|
Neuropeptides | 5 | 1997 | 951 | 0.280 |
Why?
|
Financing, Government | 4 | 2020 | 473 | 0.270 |
Why?
|
Pulmonary Emphysema | 2 | 2003 | 683 | 0.270 |
Why?
|
Pressure | 16 | 2015 | 1168 | 0.270 |
Why?
|
Receptors, Adrenergic, beta | 4 | 2001 | 242 | 0.270 |
Why?
|
Homosexuality, Male | 1 | 2015 | 1342 | 0.270 |
Why?
|
Stem Cells | 3 | 2004 | 3540 | 0.270 |
Why?
|
Cardiovascular Diseases | 6 | 2019 | 15651 | 0.270 |
Why?
|
Autocrine Communication | 2 | 2005 | 167 | 0.270 |
Why?
|
Airway Obstruction | 10 | 2003 | 665 | 0.260 |
Why?
|
Nonprescription Drugs | 2 | 2005 | 119 | 0.260 |
Why?
|
Air Pollutants | 2 | 2017 | 2923 | 0.260 |
Why?
|
Insurance Coverage | 2 | 2008 | 1944 | 0.260 |
Why?
|
Beclomethasone | 6 | 2010 | 38 | 0.260 |
Why?
|
Captopril | 7 | 1993 | 261 | 0.260 |
Why?
|
Fibrinolysin | 1 | 2006 | 129 | 0.260 |
Why?
|
Schools, Medical | 1 | 2013 | 876 | 0.260 |
Why?
|
Blood Pressure | 8 | 2015 | 8532 | 0.260 |
Why?
|
Pulmonary Ventilation | 11 | 1994 | 377 | 0.260 |
Why?
|
Plasminogen | 1 | 2006 | 144 | 0.260 |
Why?
|
Practice Guidelines as Topic | 5 | 2022 | 7425 | 0.260 |
Why?
|
Genetic Variation | 10 | 2004 | 6610 | 0.260 |
Why?
|
Thiorphan | 6 | 1992 | 10 | 0.260 |
Why?
|
Hypoglycemic Agents | 2 | 2010 | 3110 | 0.260 |
Why?
|
Decision Making | 3 | 2017 | 3965 | 0.250 |
Why?
|
Carbon Dioxide | 13 | 1998 | 1137 | 0.250 |
Why?
|
Internship and Residency | 4 | 2016 | 5946 | 0.250 |
Why?
|
Ovalbumin | 9 | 2000 | 674 | 0.250 |
Why?
|
Adverse Drug Reaction Reporting Systems | 2 | 2006 | 497 | 0.250 |
Why?
|
Drug Prescriptions | 3 | 2011 | 1662 | 0.250 |
Why?
|
Disease Management | 3 | 2015 | 2535 | 0.250 |
Why?
|
Naproxen | 1 | 2006 | 99 | 0.250 |
Why?
|
Leukoplakia, Oral | 1 | 2006 | 79 | 0.250 |
Why?
|
Pneumonectomy | 2 | 2003 | 1128 | 0.240 |
Why?
|
Rare Diseases | 1 | 2011 | 635 | 0.240 |
Why?
|
Tachykinins | 4 | 1993 | 78 | 0.240 |
Why?
|
Protease Inhibitors | 4 | 1994 | 746 | 0.240 |
Why?
|
Comparative Effectiveness Research | 1 | 2010 | 714 | 0.240 |
Why?
|
Mice, Inbred Strains | 7 | 2011 | 1770 | 0.240 |
Why?
|
JC Virus | 1 | 2005 | 87 | 0.240 |
Why?
|
Base Sequence | 15 | 2002 | 12403 | 0.240 |
Why?
|
Sulfides | 5 | 2010 | 165 | 0.240 |
Why?
|
Copyright | 1 | 2004 | 13 | 0.240 |
Why?
|
Female | 118 | 2017 | 396101 | 0.240 |
Why?
|
Clinical Trials, Phase IV as Topic | 1 | 2024 | 30 | 0.240 |
Why?
|
Indomethacin | 10 | 2000 | 322 | 0.230 |
Why?
|
Multicenter Studies as Topic | 2 | 2024 | 1731 | 0.230 |
Why?
|
Cold Temperature | 11 | 1998 | 794 | 0.230 |
Why?
|
Cells, Cultured | 19 | 2012 | 18973 | 0.230 |
Why?
|
Smoking | 8 | 2009 | 9081 | 0.230 |
Why?
|
Patient Education as Topic | 1 | 2014 | 2334 | 0.230 |
Why?
|
Hydroxyeicosatetraenoic Acids | 6 | 2003 | 225 | 0.230 |
Why?
|
Alphapapillomavirus | 1 | 2007 | 219 | 0.230 |
Why?
|
Genotype | 28 | 2005 | 13024 | 0.230 |
Why?
|
Pneumonia | 6 | 2002 | 2157 | 0.230 |
Why?
|
Cyclopropanes | 5 | 2010 | 437 | 0.230 |
Why?
|
Leukoencephalopathy, Progressive Multifocal | 1 | 2005 | 132 | 0.230 |
Why?
|
Abortion, Therapeutic | 1 | 2004 | 35 | 0.220 |
Why?
|
Opioid-Related Disorders | 1 | 2019 | 2178 | 0.220 |
Why?
|
Cyclooxygenase Inhibitors | 2 | 2005 | 361 | 0.220 |
Why?
|
Pharmacogenetics | 4 | 2004 | 682 | 0.220 |
Why?
|
Sirolimus | 1 | 2011 | 1545 | 0.220 |
Why?
|
Multiple Organ Failure | 1 | 2006 | 390 | 0.220 |
Why?
|
Cardiology | 1 | 2015 | 1702 | 0.220 |
Why?
|
Indoles | 9 | 2007 | 1839 | 0.220 |
Why?
|
NG-Nitroarginine Methyl Ester | 3 | 1998 | 261 | 0.220 |
Why?
|
Patient Protection and Affordable Care Act | 1 | 2013 | 1188 | 0.220 |
Why?
|
Receptors, Lipoxin | 4 | 2006 | 83 | 0.220 |
Why?
|
Intercellular Signaling Peptides and Proteins | 5 | 2011 | 1657 | 0.220 |
Why?
|
Antifibrinolytic Agents | 1 | 2006 | 285 | 0.210 |
Why?
|
Air Pollution | 1 | 2017 | 2380 | 0.210 |
Why?
|
Retraction of Publication as Topic | 1 | 2003 | 10 | 0.210 |
Why?
|
Marketing | 2 | 2019 | 225 | 0.210 |
Why?
|
Ethics, Medical | 2 | 2008 | 783 | 0.210 |
Why?
|
Receptors, Formyl Peptide | 4 | 2006 | 146 | 0.210 |
Why?
|
Epithelium | 11 | 2015 | 1599 | 0.210 |
Why?
|
Antineoplastic Agents | 3 | 2016 | 13648 | 0.210 |
Why?
|
Military Medicine | 1 | 2005 | 185 | 0.210 |
Why?
|
DNA | 10 | 2003 | 7202 | 0.210 |
Why?
|
Muscle Relaxation | 4 | 1994 | 138 | 0.210 |
Why?
|
Gene Frequency | 12 | 2005 | 3624 | 0.210 |
Why?
|
Hyperlipoproteinemia Type II | 1 | 2008 | 394 | 0.210 |
Why?
|
Membrane Proteins | 6 | 2005 | 7851 | 0.210 |
Why?
|
Interleukin-4 | 5 | 2004 | 1162 | 0.210 |
Why?
|
United States Dept. of Health and Human Services | 1 | 2003 | 88 | 0.200 |
Why?
|
History, 19th Century | 3 | 2012 | 711 | 0.200 |
Why?
|
Analgesics, Opioid | 1 | 2019 | 3835 | 0.200 |
Why?
|
Sulfur Dioxide | 7 | 1990 | 178 | 0.200 |
Why?
|
Transcription, Genetic | 9 | 2002 | 7599 | 0.200 |
Why?
|
Allergens | 8 | 2002 | 1436 | 0.200 |
Why?
|
Chromosomes, Human, Pair 12 | 3 | 2002 | 430 | 0.200 |
Why?
|
Pyrimidines | 2 | 2014 | 3047 | 0.200 |
Why?
|
Intellectual Property | 1 | 2002 | 32 | 0.200 |
Why?
|
Human Genome Project | 1 | 2003 | 202 | 0.200 |
Why?
|
Methacholine Compounds | 6 | 1989 | 35 | 0.200 |
Why?
|
Sepsis | 2 | 2014 | 2606 | 0.200 |
Why?
|
Extracellular Space | 1 | 2004 | 563 | 0.200 |
Why?
|
Polymorphism, Single-Stranded Conformational | 6 | 2003 | 325 | 0.200 |
Why?
|
Chromosomes, Human, Pair 20 | 1 | 2002 | 127 | 0.200 |
Why?
|
Models, Biological | 21 | 2015 | 9443 | 0.200 |
Why?
|
Pulmonary Circulation | 4 | 2002 | 741 | 0.200 |
Why?
|
Cholera Vaccines | 1 | 2005 | 264 | 0.190 |
Why?
|
Smallpox | 1 | 2002 | 43 | 0.190 |
Why?
|
Life Support Care | 1 | 2003 | 226 | 0.190 |
Why?
|
Chemokines, CC | 6 | 2002 | 285 | 0.190 |
Why?
|
Aspirin | 9 | 2006 | 3134 | 0.190 |
Why?
|
Eicosanoids | 3 | 2004 | 284 | 0.190 |
Why?
|
Smallpox Vaccine | 1 | 2002 | 77 | 0.190 |
Why?
|
Polymorphism, Single Nucleotide | 9 | 2011 | 16047 | 0.190 |
Why?
|
Blast Injuries | 1 | 2005 | 318 | 0.190 |
Why?
|
Training Support | 1 | 2002 | 109 | 0.190 |
Why?
|
Respiratory Mechanics | 5 | 2004 | 717 | 0.190 |
Why?
|
Interleukin-5 | 5 | 2002 | 268 | 0.180 |
Why?
|
Terminally Ill | 1 | 2003 | 241 | 0.180 |
Why?
|
Bioterrorism | 1 | 2002 | 144 | 0.180 |
Why?
|
Antibodies, Monoclonal | 4 | 2006 | 9249 | 0.180 |
Why?
|
Transcription Factors | 12 | 2002 | 12131 | 0.180 |
Why?
|
Statistics as Topic | 1 | 2007 | 2352 | 0.180 |
Why?
|
DNA-Binding Proteins | 11 | 2002 | 9601 | 0.180 |
Why?
|
Perfusion | 10 | 1996 | 1407 | 0.180 |
Why?
|
Up-Regulation | 3 | 2006 | 4137 | 0.180 |
Why?
|
Physicians | 3 | 2008 | 4588 | 0.180 |
Why?
|
Papillomavirus Vaccines | 1 | 2007 | 496 | 0.180 |
Why?
|
Marketing of Health Services | 1 | 2002 | 151 | 0.180 |
Why?
|
Erythema Induratum | 1 | 2000 | 3 | 0.180 |
Why?
|
Panniculitis, Nodular Nonsuppurative | 1 | 2000 | 7 | 0.180 |
Why?
|
Receptors, IgE | 1 | 2002 | 374 | 0.180 |
Why?
|
Truth Disclosure | 1 | 2005 | 433 | 0.180 |
Why?
|
Dipeptides | 7 | 1993 | 387 | 0.180 |
Why?
|
Hypersensitivity | 7 | 2012 | 1168 | 0.180 |
Why?
|
Mouth Neoplasms | 1 | 2006 | 594 | 0.180 |
Why?
|
Pacemaker, Artificial | 2 | 2008 | 827 | 0.180 |
Why?
|
Metalloendopeptidases | 1 | 2002 | 386 | 0.180 |
Why?
|
Receptors, Eicosanoid | 2 | 2014 | 12 | 0.170 |
Why?
|
Respiratory Distress Syndrome, Newborn | 1 | 2002 | 239 | 0.170 |
Why?
|
Mice | 39 | 2013 | 81818 | 0.170 |
Why?
|
Communication | 1 | 2014 | 3916 | 0.170 |
Why?
|
Endopeptidases | 2 | 1995 | 759 | 0.170 |
Why?
|
Comorbidity | 2 | 2014 | 10563 | 0.170 |
Why?
|
Nitrogen Oxides | 3 | 1995 | 128 | 0.170 |
Why?
|
RNA, Messenger | 15 | 2006 | 12769 | 0.170 |
Why?
|
Long-Term Care | 1 | 2024 | 629 | 0.170 |
Why?
|
Awards and Prizes | 1 | 2004 | 364 | 0.170 |
Why?
|
Epoprostenol | 1 | 2021 | 246 | 0.170 |
Why?
|
Cholinergic Antagonists | 3 | 2010 | 165 | 0.170 |
Why?
|
Therapies, Investigational | 1 | 2001 | 110 | 0.170 |
Why?
|
Nitric Oxide Synthase Type I | 7 | 2003 | 171 | 0.170 |
Why?
|
Lipoxins | 6 | 2006 | 419 | 0.170 |
Why?
|
Tissue and Organ Procurement | 1 | 2008 | 989 | 0.170 |
Why?
|
Molecular Sequence Data | 24 | 2006 | 17594 | 0.170 |
Why?
|
Capillary Permeability | 4 | 1998 | 768 | 0.170 |
Why?
|
Ribonucleases | 3 | 2001 | 265 | 0.170 |
Why?
|
Nifedipine | 3 | 1987 | 220 | 0.170 |
Why?
|
Chromosomes, Human, Pair 13 | 2 | 2003 | 191 | 0.160 |
Why?
|
Aortic Valve Stenosis | 2 | 2010 | 2023 | 0.160 |
Why?
|
Receptors, Histamine | 5 | 1995 | 23 | 0.160 |
Why?
|
Ozone | 4 | 1999 | 499 | 0.160 |
Why?
|
Professional-Family Relations | 1 | 2003 | 501 | 0.160 |
Why?
|
Cell Line | 9 | 2006 | 15543 | 0.160 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2014 | 3251 | 0.160 |
Why?
|
Dysmenorrhea | 1 | 2000 | 104 | 0.160 |
Why?
|
Withholding Treatment | 1 | 2003 | 621 | 0.160 |
Why?
|
Platelet-Derived Growth Factor | 1 | 2001 | 615 | 0.160 |
Why?
|
Peak Expiratory Flow Rate | 7 | 2004 | 143 | 0.160 |
Why?
|
Hospital Administration | 1 | 2002 | 352 | 0.160 |
Why?
|
Disasters | 1 | 2005 | 520 | 0.160 |
Why?
|
Medical Errors | 2 | 2004 | 1260 | 0.160 |
Why?
|
Body Fluids | 5 | 1994 | 321 | 0.160 |
Why?
|
Genes | 2 | 1999 | 1825 | 0.160 |
Why?
|
Inflammation | 11 | 2024 | 10850 | 0.150 |
Why?
|
Chromones | 5 | 1999 | 148 | 0.150 |
Why?
|
Time Factors | 30 | 2024 | 40065 | 0.150 |
Why?
|
Tissue Donors | 1 | 2008 | 2395 | 0.150 |
Why?
|
Gases | 4 | 1993 | 206 | 0.150 |
Why?
|
Cholera | 1 | 2005 | 754 | 0.150 |
Why?
|
Cholesterol, LDL | 1 | 2008 | 2393 | 0.150 |
Why?
|
Anaphylaxis | 6 | 1994 | 739 | 0.150 |
Why?
|
Prostaglandins | 8 | 2002 | 396 | 0.150 |
Why?
|
Antigens | 8 | 2000 | 1438 | 0.150 |
Why?
|
Stem Cell Transplantation | 2 | 2005 | 1602 | 0.150 |
Why?
|
Forced Expiratory Flow Rates | 7 | 2002 | 77 | 0.150 |
Why?
|
Patient Advocacy | 1 | 2000 | 361 | 0.150 |
Why?
|
Nutrition Therapy | 1 | 2019 | 101 | 0.150 |
Why?
|
Inflammation Mediators | 3 | 2012 | 1884 | 0.150 |
Why?
|
Nevada | 1 | 2017 | 20 | 0.150 |
Why?
|
Human Growth Hormone | 1 | 2003 | 638 | 0.150 |
Why?
|
Immunotherapy | 2 | 2012 | 4752 | 0.150 |
Why?
|
Chromosomes, Human, Pair 16 | 1 | 1999 | 340 | 0.150 |
Why?
|
Emergency Service, Hospital | 1 | 2017 | 7875 | 0.150 |
Why?
|
Asthma, Exercise-Induced | 4 | 1999 | 23 | 0.150 |
Why?
|
Polymerase Chain Reaction | 11 | 2003 | 6069 | 0.150 |
Why?
|
Receptors, Interleukin | 1 | 1999 | 243 | 0.140 |
Why?
|
Intensive Care Units | 5 | 2021 | 3800 | 0.140 |
Why?
|
Pulmonary Heart Disease | 1 | 2017 | 33 | 0.140 |
Why?
|
Sample Size | 1 | 2001 | 845 | 0.140 |
Why?
|
Respiratory Insufficiency | 4 | 2021 | 1240 | 0.140 |
Why?
|
Hand | 1 | 2023 | 909 | 0.140 |
Why?
|
Anti-Inflammatory Agents | 5 | 2001 | 1808 | 0.140 |
Why?
|
Genetic Linkage | 6 | 2005 | 2341 | 0.140 |
Why?
|
Gastrointestinal Diseases | 1 | 2006 | 1203 | 0.140 |
Why?
|
Adult | 77 | 2023 | 223038 | 0.140 |
Why?
|
Chronic Disease | 13 | 2016 | 9347 | 0.140 |
Why?
|
Databases, Factual | 2 | 2012 | 8067 | 0.140 |
Why?
|
Chemokines | 2 | 1999 | 956 | 0.140 |
Why?
|
Women's Health Services | 1 | 2017 | 87 | 0.140 |
Why?
|
Alleles | 13 | 2004 | 6897 | 0.140 |
Why?
|
Early Growth Response Protein 1 | 4 | 2001 | 132 | 0.140 |
Why?
|
Terminal Care | 1 | 2009 | 1774 | 0.140 |
Why?
|
Androstadienes | 4 | 2010 | 347 | 0.130 |
Why?
|
Glycoproteins | 7 | 2011 | 2195 | 0.130 |
Why?
|
Double-Blind Method | 18 | 2004 | 12437 | 0.130 |
Why?
|
Genes, Reporter | 2 | 1999 | 1524 | 0.130 |
Why?
|
Leukotriene B4 | 8 | 1987 | 281 | 0.130 |
Why?
|
Eosinophilia | 2 | 1998 | 556 | 0.130 |
Why?
|
Clinical Protocols | 1 | 2002 | 1441 | 0.130 |
Why?
|
Tumor Necrosis Factor-alpha | 4 | 2010 | 4348 | 0.130 |
Why?
|
Disease Models, Animal | 8 | 2004 | 18294 | 0.130 |
Why?
|
Multimedia | 1 | 2016 | 76 | 0.130 |
Why?
|
Body Temperature Regulation | 5 | 1990 | 292 | 0.130 |
Why?
|
Contract Services | 11 | 2001 | 89 | 0.130 |
Why?
|
Policy | 1 | 2020 | 511 | 0.130 |
Why?
|
Diagnostic Tests, Routine | 1 | 2002 | 790 | 0.130 |
Why?
|
Carrier Proteins | 2 | 1999 | 4913 | 0.130 |
Why?
|
Critical Care | 1 | 2009 | 2712 | 0.130 |
Why?
|
Phenotype | 18 | 2005 | 16721 | 0.130 |
Why?
|
gamma-Glutamyltransferase | 2 | 1993 | 140 | 0.130 |
Why?
|
Exons | 5 | 2002 | 2391 | 0.130 |
Why?
|
Military Personnel | 1 | 2005 | 1252 | 0.130 |
Why?
|
Aerosols | 16 | 1992 | 633 | 0.120 |
Why?
|
Hypertension | 1 | 2015 | 8626 | 0.120 |
Why?
|
Sympathomimetics | 2 | 2012 | 56 | 0.120 |
Why?
|
Receptors, Histamine H2 | 3 | 1980 | 18 | 0.120 |
Why?
|
Aging | 1 | 2014 | 8731 | 0.120 |
Why?
|
Atropine | 6 | 1994 | 242 | 0.120 |
Why?
|
Autacoids | 4 | 1987 | 17 | 0.120 |
Why?
|
Blood Circulation | 1 | 1996 | 248 | 0.120 |
Why?
|
Plethysmography | 6 | 2004 | 164 | 0.120 |
Why?
|
Extravascular Lung Water | 1 | 1995 | 21 | 0.120 |
Why?
|
Chemotactic Factors, Eosinophil | 3 | 1999 | 41 | 0.120 |
Why?
|
Papillomavirus Infections | 1 | 2007 | 1640 | 0.120 |
Why?
|
MAP Kinase Signaling System | 1 | 2002 | 1490 | 0.120 |
Why?
|
Medically Uninsured | 1 | 2000 | 838 | 0.120 |
Why?
|
Adolescent | 32 | 2023 | 88832 | 0.120 |
Why?
|
Florida | 1 | 2016 | 416 | 0.120 |
Why?
|
P-Selectin | 1 | 1997 | 597 | 0.120 |
Why?
|
Stents | 1 | 2007 | 3213 | 0.120 |
Why?
|
Leukocytes | 3 | 2003 | 2027 | 0.120 |
Why?
|
Trans-Activators | 4 | 2004 | 2850 | 0.120 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2007 | 2047 | 0.120 |
Why?
|
Self Disclosure | 1 | 2016 | 248 | 0.120 |
Why?
|
Microcirculation | 2 | 1998 | 1280 | 0.120 |
Why?
|
Hypersensitivity, Immediate | 5 | 2003 | 346 | 0.120 |
Why?
|
Heart Transplantation | 1 | 2008 | 3310 | 0.120 |
Why?
|
Prostaglandins F | 6 | 1982 | 79 | 0.120 |
Why?
|
Compressive Strength | 3 | 2005 | 159 | 0.110 |
Why?
|
Benzamides | 3 | 2011 | 1377 | 0.110 |
Why?
|
Pyrazoles | 1 | 2005 | 2033 | 0.110 |
Why?
|
Pulmonary Medicine | 2 | 2014 | 222 | 0.110 |
Why?
|
Stereotyping | 1 | 2016 | 242 | 0.110 |
Why?
|
Platelet Activating Factor | 2 | 1991 | 142 | 0.110 |
Why?
|
Fluocinolone Acetonide | 3 | 2004 | 38 | 0.110 |
Why?
|
Receptors, Cell Surface | 6 | 2006 | 2817 | 0.110 |
Why?
|
Data Interpretation, Statistical | 4 | 2007 | 2686 | 0.110 |
Why?
|
Total Lung Capacity | 8 | 1998 | 148 | 0.110 |
Why?
|
Cell Shape | 1 | 2015 | 373 | 0.110 |
Why?
|
Renal Dialysis | 1 | 2003 | 1799 | 0.110 |
Why?
|
Ligands | 6 | 2014 | 3273 | 0.110 |
Why?
|
Cell Communication | 1 | 2001 | 1660 | 0.110 |
Why?
|
Nicotine | 1 | 2019 | 682 | 0.110 |
Why?
|
Arachidonic Acid | 5 | 1999 | 430 | 0.110 |
Why?
|
Cysteine | 4 | 2011 | 898 | 0.110 |
Why?
|
Injections, Intravenous | 4 | 2008 | 1377 | 0.110 |
Why?
|
Mutation, Missense | 1 | 2003 | 2589 | 0.110 |
Why?
|
Cloning, Organism | 2 | 2004 | 50 | 0.110 |
Why?
|
Pharmaceutical Preparations | 1 | 2002 | 1084 | 0.110 |
Why?
|
Sleep Apnea Syndromes | 1 | 2002 | 969 | 0.110 |
Why?
|
Cystic Fibrosis | 5 | 2002 | 1287 | 0.110 |
Why?
|
Neoplasms | 3 | 2019 | 22340 | 0.110 |
Why?
|
Signal Transduction | 9 | 2014 | 23600 | 0.110 |
Why?
|
Internationality | 2 | 2016 | 1007 | 0.110 |
Why?
|
Therapeutic Equipoise | 1 | 2013 | 29 | 0.110 |
Why?
|
Propranolol | 7 | 1989 | 492 | 0.110 |
Why?
|
Extracellular Matrix | 1 | 2001 | 1727 | 0.110 |
Why?
|
Body Temperature | 2 | 1987 | 779 | 0.110 |
Why?
|
Brain Injuries | 1 | 2005 | 2060 | 0.110 |
Why?
|
Infant, Premature | 1 | 2023 | 2122 | 0.110 |
Why?
|
Carbachol | 7 | 1986 | 223 | 0.100 |
Why?
|
Risk | 3 | 2013 | 9591 | 0.100 |
Why?
|
Organizations | 1 | 2014 | 172 | 0.100 |
Why?
|
Clinical Competence | 2 | 2022 | 4863 | 0.100 |
Why?
|
Lung Diseases, Interstitial | 2 | 2021 | 939 | 0.100 |
Why?
|
Receptors, Serotonin | 1 | 1994 | 209 | 0.100 |
Why?
|
Nasal Mucosa | 2 | 2002 | 416 | 0.100 |
Why?
|
Peptide Fragments | 4 | 1994 | 5125 | 0.100 |
Why?
|
Guidelines as Topic | 3 | 2016 | 1394 | 0.100 |
Why?
|
Antiretroviral Therapy, Highly Active | 1 | 2001 | 1899 | 0.100 |
Why?
|
Interleukin-13 | 3 | 2004 | 388 | 0.100 |
Why?
|
Lod Score | 4 | 2002 | 598 | 0.100 |
Why?
|
Mice, Knockout | 9 | 2011 | 14447 | 0.100 |
Why?
|
Datura stramonium | 1 | 2012 | 3 | 0.100 |
Why?
|
Algorithms | 2 | 2023 | 14071 | 0.100 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 2001 | 2203 | 0.100 |
Why?
|
Rhinitis, Allergic, Seasonal | 2 | 2012 | 101 | 0.100 |
Why?
|
Coronary Disease | 1 | 2007 | 5912 | 0.100 |
Why?
|
Isoproterenol | 7 | 2000 | 398 | 0.100 |
Why?
|
Calcium Channel Blockers | 2 | 1987 | 686 | 0.100 |
Why?
|
Drug Hypersensitivity | 4 | 1998 | 902 | 0.100 |
Why?
|
Ephedrine | 1 | 2012 | 54 | 0.100 |
Why?
|
Immunoblotting | 2 | 2010 | 1644 | 0.100 |
Why?
|
Metaplasia | 1 | 2013 | 326 | 0.100 |
Why?
|
Serotonin | 3 | 1994 | 1047 | 0.100 |
Why?
|
Cross-Over Studies | 5 | 2010 | 2108 | 0.100 |
Why?
|
Terminology as Topic | 4 | 2011 | 1534 | 0.100 |
Why?
|
Contraception, Postcoital | 1 | 2011 | 20 | 0.100 |
Why?
|
Maximal Expiratory Flow-Volume Curves | 4 | 1987 | 25 | 0.100 |
Why?
|
Pyrilamine | 5 | 1995 | 13 | 0.100 |
Why?
|
Middle Aged | 50 | 2012 | 223004 | 0.100 |
Why?
|
Triamcinolone Acetonide | 3 | 2001 | 105 | 0.090 |
Why?
|
China | 2 | 2016 | 2385 | 0.090 |
Why?
|
Texas | 1 | 2013 | 410 | 0.090 |
Why?
|
Pulmonary Artery | 4 | 2002 | 1935 | 0.090 |
Why?
|
Fibroblasts | 4 | 2011 | 4159 | 0.090 |
Why?
|
Mice, Inbred C57BL | 11 | 2011 | 22331 | 0.090 |
Why?
|
Professional Competence | 1 | 2014 | 429 | 0.090 |
Why?
|
Ethics Committees, Research | 2 | 2004 | 197 | 0.090 |
Why?
|
Vermont | 1 | 2011 | 80 | 0.090 |
Why?
|
Acute Kidney Injury | 1 | 2003 | 1946 | 0.090 |
Why?
|
Neutrophils | 11 | 2001 | 3776 | 0.090 |
Why?
|
Video Recording | 1 | 2016 | 969 | 0.090 |
Why?
|
Ownership | 1 | 2014 | 338 | 0.090 |
Why?
|
Nerve Tissue Proteins | 2 | 2000 | 4392 | 0.090 |
Why?
|
Treatment Outcome | 16 | 2024 | 65189 | 0.090 |
Why?
|
Phosphorylation | 4 | 2010 | 8278 | 0.090 |
Why?
|
Foundations | 1 | 2011 | 95 | 0.090 |
Why?
|
Infant, Newborn | 3 | 2023 | 26349 | 0.090 |
Why?
|
Matrix Metalloproteinase 9 | 2 | 2006 | 636 | 0.090 |
Why?
|
Patient Care Team | 2 | 2016 | 2517 | 0.090 |
Why?
|
Patient Acceptance of Health Care | 1 | 2024 | 3229 | 0.090 |
Why?
|
Arthritis, Rheumatoid | 1 | 2006 | 3733 | 0.090 |
Why?
|
Cell Count | 4 | 2011 | 1823 | 0.090 |
Why?
|
Antigens, CD | 2 | 1999 | 4025 | 0.090 |
Why?
|
Vital Capacity | 9 | 2002 | 995 | 0.090 |
Why?
|
Hypertension, Pulmonary | 1 | 2021 | 1604 | 0.090 |
Why?
|
Mucus | 6 | 1988 | 346 | 0.090 |
Why?
|
Interferon-gamma | 3 | 1997 | 3160 | 0.080 |
Why?
|
Dietary Supplements | 1 | 2003 | 3426 | 0.080 |
Why?
|
Phytotherapy | 1 | 2012 | 298 | 0.080 |
Why?
|
Advance Care Planning | 1 | 2017 | 702 | 0.080 |
Why?
|
Personnel Staffing and Scheduling | 2 | 2004 | 499 | 0.080 |
Why?
|
Research | 2 | 2010 | 1975 | 0.080 |
Why?
|
Tuberculosis | 1 | 2002 | 2012 | 0.080 |
Why?
|
Cultural Competency | 1 | 2013 | 303 | 0.080 |
Why?
|
Maximal Expiratory Flow Rate | 5 | 1989 | 42 | 0.080 |
Why?
|
Neurokinin B | 1 | 1989 | 67 | 0.080 |
Why?
|
Piperidines | 2 | 1995 | 1664 | 0.080 |
Why?
|
Pulmonary Eosinophilia | 2 | 2000 | 78 | 0.080 |
Why?
|
Mice, Inbred BALB C | 6 | 2004 | 6220 | 0.080 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 1999 | 2880 | 0.080 |
Why?
|
Paracrine Communication | 1 | 2011 | 277 | 0.080 |
Why?
|
Elasticity | 3 | 2006 | 652 | 0.080 |
Why?
|
Nitroso Compounds | 3 | 1994 | 70 | 0.080 |
Why?
|
Theophylline | 1 | 1989 | 132 | 0.080 |
Why?
|
South Dakota | 1 | 2008 | 32 | 0.080 |
Why?
|
Single-Blind Method | 6 | 2004 | 1588 | 0.080 |
Why?
|
Proteins | 5 | 1999 | 5995 | 0.080 |
Why?
|
Mutation | 10 | 2002 | 30196 | 0.080 |
Why?
|
Triamcinolone | 3 | 2002 | 68 | 0.080 |
Why?
|
Oligodeoxyribonucleotides | 3 | 2003 | 705 | 0.080 |
Why?
|
B-Lymphocytes | 2 | 1999 | 4778 | 0.080 |
Why?
|
Guanidines | 2 | 1998 | 194 | 0.080 |
Why?
|
Gene Expression Regulation, Enzymologic | 3 | 1999 | 1167 | 0.080 |
Why?
|
Repressor Proteins | 1 | 1999 | 2968 | 0.080 |
Why?
|
Receptors, Adrenergic | 1 | 1988 | 155 | 0.080 |
Why?
|
Reproductive Rights | 1 | 2008 | 31 | 0.080 |
Why?
|
Lysophospholipids | 1 | 2011 | 335 | 0.080 |
Why?
|
Travel | 1 | 2014 | 806 | 0.080 |
Why?
|
Tamoxifen | 1 | 2013 | 963 | 0.080 |
Why?
|
Amino Acid Sequence | 12 | 2004 | 13400 | 0.080 |
Why?
|
Blotting, Northern | 4 | 2004 | 1546 | 0.080 |
Why?
|
Pulmonary Surfactants | 1 | 1989 | 169 | 0.080 |
Why?
|
Tiopronin | 1 | 1988 | 3 | 0.080 |
Why?
|
Amino Acids, Sulfur | 1 | 1988 | 16 | 0.080 |
Why?
|
Enzyme Activation | 3 | 2006 | 3586 | 0.070 |
Why?
|
Respiratory Dead Space | 3 | 1983 | 31 | 0.070 |
Why?
|
Lectins | 1 | 2010 | 487 | 0.070 |
Why?
|
Crosses, Genetic | 3 | 2005 | 752 | 0.070 |
Why?
|
Spirometry | 6 | 2003 | 929 | 0.070 |
Why?
|
Integrases | 1 | 2010 | 520 | 0.070 |
Why?
|
Extracellular Signal-Regulated MAP Kinases | 1 | 2010 | 612 | 0.070 |
Why?
|
Obesity | 1 | 2010 | 13075 | 0.070 |
Why?
|
Isoxazoles | 2 | 2005 | 234 | 0.070 |
Why?
|
District of Columbia | 1 | 2008 | 159 | 0.070 |
Why?
|
Mice, Inbred A | 2 | 1999 | 244 | 0.070 |
Why?
|
Tunica Media | 1 | 2008 | 107 | 0.070 |
Why?
|
Communicable Disease Control | 1 | 2014 | 856 | 0.070 |
Why?
|
Risk Assessment | 4 | 2019 | 24283 | 0.070 |
Why?
|
Product Labeling | 1 | 2008 | 75 | 0.070 |
Why?
|
Mucous Membrane | 4 | 2002 | 657 | 0.070 |
Why?
|
Reference Values | 5 | 2006 | 4908 | 0.070 |
Why?
|
Catheterization | 1 | 1993 | 1425 | 0.070 |
Why?
|
Antibodies, Anti-Idiotypic | 1 | 1989 | 340 | 0.070 |
Why?
|
Fish Oils | 3 | 1986 | 483 | 0.070 |
Why?
|
N-Formylmethionine Leucyl-Phenylalanine | 1 | 1987 | 218 | 0.070 |
Why?
|
Local Government | 1 | 2008 | 83 | 0.070 |
Why?
|
Proto-Oncogene Proteins c-kit | 1 | 2011 | 723 | 0.070 |
Why?
|
Coculture Techniques | 2 | 2001 | 1336 | 0.070 |
Why?
|
Protein Biosynthesis | 3 | 2003 | 2086 | 0.070 |
Why?
|
Child | 16 | 2023 | 80563 | 0.070 |
Why?
|
Sodium Glutamate | 1 | 1987 | 22 | 0.070 |
Why?
|
Kinetics | 9 | 1993 | 6274 | 0.070 |
Why?
|
World Health Organization | 2 | 2010 | 1328 | 0.070 |
Why?
|
Mathematics | 6 | 1987 | 696 | 0.070 |
Why?
|
Quality Control | 2 | 2007 | 837 | 0.070 |
Why?
|
Diabetes Mellitus, Type 2 | 2 | 2010 | 12240 | 0.070 |
Why?
|
Peroxidases | 3 | 2002 | 134 | 0.070 |
Why?
|
Helium | 8 | 1993 | 119 | 0.070 |
Why?
|
Parkinson Disease | 1 | 2001 | 2895 | 0.070 |
Why?
|
Mexican Americans | 2 | 2004 | 165 | 0.070 |
Why?
|
Breath Tests | 3 | 2003 | 297 | 0.070 |
Why?
|
Aged, 80 and over | 6 | 2017 | 59488 | 0.070 |
Why?
|
Resuscitation Orders | 1 | 2009 | 275 | 0.070 |
Why?
|
Receptors, Prostaglandin | 3 | 1995 | 54 | 0.070 |
Why?
|
Receptors, Urokinase Plasminogen Activator | 1 | 2006 | 74 | 0.070 |
Why?
|
Gene Expression Regulation | 4 | 2011 | 11888 | 0.070 |
Why?
|
Public Opinion | 1 | 2010 | 482 | 0.070 |
Why?
|
DNA Primers | 4 | 2003 | 2825 | 0.070 |
Why?
|
Age Factors | 4 | 2019 | 18380 | 0.070 |
Why?
|
Analysis of Variance | 8 | 2001 | 6203 | 0.070 |
Why?
|
Polymorphism, Restriction Fragment Length | 3 | 2003 | 766 | 0.070 |
Why?
|
Placebos | 1 | 2010 | 1659 | 0.060 |
Why?
|
Pregnancy | 6 | 2016 | 30258 | 0.060 |
Why?
|
National Library of Medicine (U.S.) | 1 | 2005 | 34 | 0.060 |
Why?
|
Data Mining | 1 | 2011 | 562 | 0.060 |
Why?
|
Delivery of Health Care | 1 | 2024 | 5369 | 0.060 |
Why?
|
Safety | 3 | 1999 | 1157 | 0.060 |
Why?
|
Sequence Analysis, DNA | 4 | 2001 | 4772 | 0.060 |
Why?
|
Transforming Growth Factor beta2 | 2 | 2004 | 71 | 0.060 |
Why?
|
Tunica Intima | 1 | 2008 | 455 | 0.060 |
Why?
|
Chromatography, High Pressure Liquid | 5 | 1995 | 1526 | 0.060 |
Why?
|
Nitric Oxide Synthase Type III | 3 | 2003 | 707 | 0.060 |
Why?
|
Health Benefit Plans, Employee | 1 | 2008 | 331 | 0.060 |
Why?
|
Industry | 1 | 2008 | 362 | 0.060 |
Why?
|
Rats | 12 | 2001 | 23707 | 0.060 |
Why?
|
Constriction, Pathologic | 6 | 1992 | 1105 | 0.060 |
Why?
|
Chemokine CCL11 | 6 | 2002 | 127 | 0.060 |
Why?
|
Glutamates | 1 | 1987 | 384 | 0.060 |
Why?
|
Quality of Health Care | 1 | 2000 | 4300 | 0.060 |
Why?
|
Anesthetics | 2 | 1993 | 525 | 0.060 |
Why?
|
Cardiomyopathies | 1 | 1998 | 2067 | 0.060 |
Why?
|
Minority Groups | 1 | 2013 | 1207 | 0.060 |
Why?
|
Models, Genetic | 3 | 2000 | 3448 | 0.060 |
Why?
|
Sputum | 2 | 2001 | 513 | 0.060 |
Why?
|
Amino Acid Oxidoreductases | 3 | 1994 | 149 | 0.060 |
Why?
|
Urokinase-Type Plasminogen Activator | 1 | 2006 | 323 | 0.060 |
Why?
|
Iraq | 1 | 2005 | 93 | 0.060 |
Why?
|
Influenza A Virus, H1N1 Subtype | 1 | 2009 | 452 | 0.060 |
Why?
|
Molecular Conformation | 1 | 2006 | 541 | 0.060 |
Why?
|
Drug Administration Schedule | 5 | 2004 | 4850 | 0.060 |
Why?
|
Tandem Repeat Sequences | 3 | 2002 | 184 | 0.060 |
Why?
|
Plasminogen Activator Inhibitor 1 | 1 | 2006 | 281 | 0.060 |
Why?
|
Serine Endopeptidases | 3 | 2001 | 1024 | 0.060 |
Why?
|
Cyclooxygenase 2 | 2 | 2005 | 594 | 0.060 |
Why?
|
Ethics, Research | 1 | 2006 | 178 | 0.060 |
Why?
|
Receptors, Neurokinin-2 | 2 | 1995 | 23 | 0.060 |
Why?
|
Asia, Southeastern | 1 | 2005 | 115 | 0.060 |
Why?
|
Receptors, Immunologic | 1 | 1991 | 1415 | 0.060 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 2 | 1991 | 1514 | 0.060 |
Why?
|
Intubation | 1 | 1985 | 141 | 0.060 |
Why?
|
Hospitalists | 1 | 2009 | 297 | 0.060 |
Why?
|
Infusions, Intravenous | 3 | 1998 | 2229 | 0.060 |
Why?
|
T-Box Domain Proteins | 2 | 2004 | 469 | 0.060 |
Why?
|
Functional Residual Capacity | 4 | 1994 | 70 | 0.060 |
Why?
|
Adoptive Transfer | 3 | 2011 | 827 | 0.060 |
Why?
|
Intubation, Intratracheal | 4 | 1996 | 1303 | 0.060 |
Why?
|
Enzyme Inhibitors | 4 | 2005 | 3715 | 0.060 |
Why?
|
Bradykinin | 2 | 1975 | 205 | 0.060 |
Why?
|
Sequence Deletion | 3 | 1997 | 1495 | 0.060 |
Why?
|
Aged | 18 | 2014 | 171114 | 0.060 |
Why?
|
Receptors, Neurokinin-1 | 2 | 1995 | 133 | 0.060 |
Why?
|
Endothelin-1 | 2 | 2003 | 295 | 0.060 |
Why?
|
Matrix Metalloproteinase 2 | 1 | 2006 | 462 | 0.060 |
Why?
|
Case-Control Studies | 9 | 2003 | 22222 | 0.060 |
Why?
|
Circadian Rhythm | 1 | 1995 | 2590 | 0.060 |
Why?
|
Acute Disease | 5 | 1999 | 7232 | 0.060 |
Why?
|
Coronary Thrombosis | 1 | 2007 | 440 | 0.060 |
Why?
|
Dyspnea | 1 | 2012 | 1352 | 0.060 |
Why?
|
Osmolar Concentration | 3 | 1991 | 655 | 0.060 |
Why?
|
Exercise | 2 | 2001 | 5937 | 0.060 |
Why?
|
Pleura | 1 | 1985 | 240 | 0.060 |
Why?
|
Emergencies | 2 | 2004 | 1223 | 0.050 |
Why?
|
Receptors, Corticotropin-Releasing Hormone | 1 | 2004 | 88 | 0.050 |
Why?
|
Dinoprostone | 2 | 1997 | 591 | 0.050 |
Why?
|
Speech | 1 | 2008 | 555 | 0.050 |
Why?
|
Molecular Targeted Therapy | 2 | 2012 | 2822 | 0.050 |
Why?
|
Water Supply | 1 | 2005 | 204 | 0.050 |
Why?
|
Statistics, Nonparametric | 4 | 2003 | 2845 | 0.050 |
Why?
|
RNA | 3 | 2001 | 2717 | 0.050 |
Why?
|
Health Insurance Portability and Accountability Act | 1 | 2004 | 104 | 0.050 |
Why?
|
Confidence Intervals | 2 | 2007 | 2910 | 0.050 |
Why?
|
Rabbits | 4 | 2001 | 4734 | 0.050 |
Why?
|
Dietary Fats | 3 | 1986 | 2002 | 0.050 |
Why?
|
Cloning, Molecular | 5 | 2001 | 4165 | 0.050 |
Why?
|
Endothelin-2 | 1 | 2003 | 2 | 0.050 |
Why?
|
Mercaptoethanol | 2 | 1994 | 61 | 0.050 |
Why?
|
Cimetidine | 2 | 1980 | 76 | 0.050 |
Why?
|
Cardiotonic Agents | 1 | 1986 | 538 | 0.050 |
Why?
|
Bone Marrow Transplantation | 4 | 2001 | 2729 | 0.050 |
Why?
|
Organ Specificity | 3 | 2011 | 1965 | 0.050 |
Why?
|
S-Nitrosothiols | 2 | 1994 | 35 | 0.050 |
Why?
|
Electric Stimulation | 8 | 1986 | 1735 | 0.050 |
Why?
|
Diagnosis, Differential | 5 | 2008 | 12976 | 0.050 |
Why?
|
Pica | 1 | 2003 | 37 | 0.050 |
Why?
|
Administration, Oral | 1 | 2011 | 4015 | 0.050 |
Why?
|
Collagen | 2 | 2001 | 2618 | 0.050 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 3 | 2011 | 4562 | 0.050 |
Why?
|
Species Specificity | 2 | 1997 | 2406 | 0.050 |
Why?
|
Stress, Physiological | 1 | 2010 | 1402 | 0.050 |
Why?
|
Myocardial Infarction | 3 | 2010 | 11501 | 0.050 |
Why?
|
International Agencies | 3 | 2011 | 240 | 0.050 |
Why?
|
Reimbursement Mechanisms | 1 | 2008 | 672 | 0.050 |
Why?
|
Leukotriene C4 | 1 | 2003 | 79 | 0.050 |
Why?
|
Freedom | 1 | 2002 | 69 | 0.050 |
Why?
|
Variola virus | 1 | 2002 | 12 | 0.050 |
Why?
|
Hyperventilation | 4 | 1998 | 78 | 0.050 |
Why?
|
Biomedical Engineering | 1 | 1984 | 284 | 0.050 |
Why?
|
Air | 4 | 1996 | 181 | 0.050 |
Why?
|
Medicare | 1 | 2000 | 6823 | 0.050 |
Why?
|
Biopsy | 2 | 2012 | 6763 | 0.050 |
Why?
|
Structure-Activity Relationship | 8 | 1997 | 3051 | 0.050 |
Why?
|
Population | 1 | 2002 | 140 | 0.050 |
Why?
|
Aneuploidy | 1 | 2006 | 578 | 0.050 |
Why?
|
Tryptases | 3 | 2001 | 177 | 0.050 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2010 | 2453 | 0.050 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2011 | 2056 | 0.050 |
Why?
|
Reflex | 2 | 1981 | 376 | 0.050 |
Why?
|
Diaphragm | 1 | 1983 | 356 | 0.050 |
Why?
|
Osmotic Pressure | 1 | 2002 | 136 | 0.050 |
Why?
|
Th1 Cells | 2 | 2004 | 1039 | 0.050 |
Why?
|
Calcium | 4 | 2003 | 5767 | 0.050 |
Why?
|
Pulmonary Diffusing Capacity | 1 | 2001 | 93 | 0.050 |
Why?
|
Enzyme Induction | 2 | 1999 | 456 | 0.050 |
Why?
|
Culture Media, Conditioned | 1 | 2003 | 522 | 0.050 |
Why?
|
Interinstitutional Relations | 1 | 2002 | 234 | 0.050 |
Why?
|
Sulfhydryl Compounds | 2 | 1993 | 296 | 0.050 |
Why?
|
Genetic Code | 1 | 2001 | 139 | 0.050 |
Why?
|
Th2 Cells | 2 | 2004 | 1075 | 0.050 |
Why?
|
Recombinant Proteins | 6 | 1998 | 6493 | 0.050 |
Why?
|
Models, Structural | 1 | 1981 | 338 | 0.050 |
Why?
|
Budesonide | 3 | 2002 | 163 | 0.050 |
Why?
|
Quantitative Trait, Heritable | 2 | 2005 | 541 | 0.050 |
Why?
|
Stereoisomerism | 5 | 1987 | 614 | 0.050 |
Why?
|
Ascaris | 1 | 1980 | 26 | 0.050 |
Why?
|
Pyridones | 1 | 1986 | 816 | 0.050 |
Why?
|
Coronavirus | 1 | 2003 | 155 | 0.050 |
Why?
|
Lymphatic Diseases | 1 | 2002 | 317 | 0.040 |
Why?
|
Tissue Inhibitor of Metalloproteinase-1 | 1 | 2001 | 150 | 0.040 |
Why?
|
Blastocyst | 1 | 2004 | 432 | 0.040 |
Why?
|
Transforming Growth Factor beta | 3 | 2004 | 1995 | 0.040 |
Why?
|
Dinucleotide Repeats | 1 | 2000 | 28 | 0.040 |
Why?
|
Pyrroles | 1 | 2007 | 1119 | 0.040 |
Why?
|
Pyridines | 2 | 1983 | 2888 | 0.040 |
Why?
|
Haplotypes | 3 | 2004 | 2728 | 0.040 |
Why?
|
Models, Anatomic | 2 | 1981 | 677 | 0.040 |
Why?
|
DNA, Neoplasm | 1 | 2006 | 1742 | 0.040 |
Why?
|
Tissue Plasminogen Activator | 1 | 2006 | 1167 | 0.040 |
Why?
|
Microscopy, Electron, Scanning | 3 | 1994 | 939 | 0.040 |
Why?
|
Adaptor Protein Complex alpha Subunits | 1 | 2000 | 23 | 0.040 |
Why?
|
Cats | 1 | 2001 | 972 | 0.040 |
Why?
|
DNA Probes | 1 | 2001 | 541 | 0.040 |
Why?
|
Colchicine | 2 | 2001 | 256 | 0.040 |
Why?
|
Triglycerides | 1 | 2008 | 2441 | 0.040 |
Why?
|
Models, Theoretical | 1 | 1992 | 3564 | 0.040 |
Why?
|
Immunohistochemistry | 6 | 2004 | 11022 | 0.040 |
Why?
|
Hospitalization | 1 | 2020 | 10808 | 0.040 |
Why?
|
Leukotriene A4 | 1 | 1999 | 24 | 0.040 |
Why?
|
Chromosomes, Human | 1 | 2002 | 437 | 0.040 |
Why?
|
Drug Therapy | 1 | 2003 | 504 | 0.040 |
Why?
|
Gout Suppressants | 2 | 2001 | 176 | 0.040 |
Why?
|
Calcimycin | 2 | 1990 | 214 | 0.040 |
Why?
|
Eosinophil Granule Proteins | 2 | 2001 | 28 | 0.040 |
Why?
|
Uterine Contraction | 1 | 2000 | 90 | 0.040 |
Why?
|
Chromosomes, Artificial, Yeast | 1 | 1999 | 112 | 0.040 |
Why?
|
Multiple Sclerosis, Relapsing-Remitting | 1 | 2005 | 550 | 0.040 |
Why?
|
Prosthesis Design | 1 | 2007 | 2105 | 0.040 |
Why?
|
Sickness Impact Profile | 1 | 2001 | 297 | 0.040 |
Why?
|
Family | 2 | 2009 | 3209 | 0.040 |
Why?
|
Injections, Subcutaneous | 1 | 2021 | 682 | 0.040 |
Why?
|
Introns | 1 | 2002 | 966 | 0.040 |
Why?
|
Primary Health Care | 2 | 2023 | 4736 | 0.040 |
Why?
|
Hybrid Cells | 1 | 1999 | 421 | 0.040 |
Why?
|
Recurrence | 1 | 2012 | 8501 | 0.040 |
Why?
|
Gene Targeting | 2 | 2002 | 841 | 0.040 |
Why?
|
Point Mutation | 2 | 2001 | 1590 | 0.040 |
Why?
|
T-Lymphocytes | 1 | 1997 | 10261 | 0.040 |
Why?
|
Thromboembolism | 1 | 2006 | 1003 | 0.040 |
Why?
|
Health Services Accessibility | 2 | 2008 | 5506 | 0.040 |
Why?
|
Health Policy | 1 | 2011 | 2698 | 0.040 |
Why?
|
Spinal Fusion | 1 | 2009 | 1302 | 0.040 |
Why?
|
Chloramphenicol O-Acetyltransferase | 1 | 1999 | 220 | 0.040 |
Why?
|
Sensitivity and Specificity | 5 | 2008 | 14652 | 0.040 |
Why?
|
Cluster Analysis | 1 | 2006 | 2720 | 0.040 |
Why?
|
Receptors, Interleukin-8A | 1 | 1999 | 47 | 0.040 |
Why?
|
5-Lipoxygenase-Activating Proteins | 1 | 1999 | 24 | 0.040 |
Why?
|
Thiourea | 1 | 1979 | 69 | 0.040 |
Why?
|
National Health Programs | 1 | 2002 | 443 | 0.040 |
Why?
|
Commerce | 1 | 2004 | 611 | 0.040 |
Why?
|
Tobacco Smoke Pollution | 1 | 2005 | 827 | 0.040 |
Why?
|
Phospholipases A | 1 | 1999 | 204 | 0.040 |
Why?
|
Drug Interactions | 4 | 1991 | 1417 | 0.040 |
Why?
|
Flavonoids | 1 | 2002 | 448 | 0.040 |
Why?
|
Acetophenones | 2 | 1989 | 51 | 0.040 |
Why?
|
Weight Loss | 1 | 2010 | 2710 | 0.040 |
Why?
|
Vibrio cholerae | 1 | 2005 | 793 | 0.040 |
Why?
|
Suppressor of Cytokine Signaling Proteins | 1 | 1999 | 178 | 0.040 |
Why?
|
Physical Chromosome Mapping | 1 | 1999 | 183 | 0.040 |
Why?
|
Bronchoalveolar Lavage | 1 | 1999 | 131 | 0.040 |
Why?
|
Population Surveillance | 1 | 2009 | 2590 | 0.040 |
Why?
|
Research Subjects | 1 | 2000 | 247 | 0.040 |
Why?
|
Oxidants, Photochemical | 1 | 1999 | 77 | 0.040 |
Why?
|
Canada | 1 | 2004 | 2119 | 0.040 |
Why?
|
CpG Islands | 1 | 2003 | 1207 | 0.040 |
Why?
|
Membrane Lipids | 1 | 1999 | 240 | 0.040 |
Why?
|
Linkage Disequilibrium | 4 | 2005 | 1997 | 0.040 |
Why?
|
Computer Simulation | 3 | 2015 | 6255 | 0.040 |
Why?
|
Mice, Inbred C3H | 1 | 1999 | 914 | 0.040 |
Why?
|
Education, Distance | 1 | 2022 | 261 | 0.040 |
Why?
|
Pregnenediones | 2 | 1996 | 29 | 0.040 |
Why?
|
Tablets | 1 | 1998 | 149 | 0.040 |
Why?
|
Amiloride | 1 | 1998 | 115 | 0.040 |
Why?
|
Heart Arrest | 1 | 2008 | 1516 | 0.040 |
Why?
|
Glutathione Transferase | 1 | 2000 | 562 | 0.040 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2004 | 891 | 0.040 |
Why?
|
Allosteric Regulation | 1 | 1999 | 425 | 0.040 |
Why?
|
Aminophylline | 2 | 1989 | 41 | 0.040 |
Why?
|
Adrenal Glands | 2 | 1996 | 558 | 0.040 |
Why?
|
Adaptor Proteins, Vesicular Transport | 1 | 2000 | 298 | 0.040 |
Why?
|
Pneumonia, Bacterial | 1 | 2001 | 318 | 0.040 |
Why?
|
Europe | 1 | 2005 | 3423 | 0.040 |
Why?
|
Histocytochemistry | 1 | 1999 | 696 | 0.040 |
Why?
|
Infusions, Parenteral | 4 | 1982 | 395 | 0.040 |
Why?
|
Blood Cell Count | 1 | 1999 | 405 | 0.040 |
Why?
|
Influenza, Human | 1 | 2009 | 1539 | 0.040 |
Why?
|
Sp1 Transcription Factor | 1 | 1998 | 143 | 0.040 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2006 | 3796 | 0.040 |
Why?
|
Pedigree | 4 | 2011 | 4526 | 0.040 |
Why?
|
Cardiac Pacing, Artificial | 1 | 2002 | 881 | 0.040 |
Why?
|
Flow Cytometry | 2 | 1999 | 5881 | 0.040 |
Why?
|
5' Untranslated Regions | 1 | 1999 | 256 | 0.040 |
Why?
|
Receptors, Chemokine | 1 | 2000 | 651 | 0.040 |
Why?
|
Gastrointestinal Hemorrhage | 1 | 2005 | 1127 | 0.040 |
Why?
|
Fibronectins | 1 | 2001 | 719 | 0.040 |
Why?
|
Inspiratory Capacity | 2 | 1994 | 35 | 0.040 |
Why?
|
6-Ketoprostaglandin F1 alpha | 1 | 1997 | 80 | 0.040 |
Why?
|
Aquaporins | 1 | 1998 | 176 | 0.040 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 4 | 2000 | 3807 | 0.030 |
Why?
|
Plethysmography, Whole Body | 2 | 1988 | 25 | 0.030 |
Why?
|
Mitogen-Activated Protein Kinases | 1 | 2002 | 1240 | 0.030 |
Why?
|
Retroviridae Proteins, Oncogenic | 1 | 1997 | 74 | 0.030 |
Why?
|
Codon, Initiator | 1 | 1997 | 50 | 0.030 |
Why?
|
Biotransformation | 2 | 1991 | 165 | 0.030 |
Why?
|
Vagotomy | 1 | 1997 | 82 | 0.030 |
Why?
|
Role | 1 | 2017 | 176 | 0.030 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2001 | 616 | 0.030 |
Why?
|
Isomerism | 1 | 1997 | 197 | 0.030 |
Why?
|
Heart | 2 | 1993 | 4414 | 0.030 |
Why?
|
Sarcoidosis | 1 | 2002 | 532 | 0.030 |
Why?
|
Mice, Mutant Strains | 4 | 1999 | 1745 | 0.030 |
Why?
|
Adrenergic beta-Antagonists | 2 | 1981 | 1237 | 0.030 |
Why?
|
Menstrual Cycle | 1 | 2000 | 540 | 0.030 |
Why?
|
Equipment Design | 1 | 2005 | 3481 | 0.030 |
Why?
|
Angiogenesis Inhibitors | 1 | 2007 | 2056 | 0.030 |
Why?
|
Random Allocation | 3 | 1997 | 2395 | 0.030 |
Why?
|
Leukocyte Count | 5 | 2001 | 1602 | 0.030 |
Why?
|
Chromosomes | 1 | 1999 | 578 | 0.030 |
Why?
|
Constriction | 3 | 1989 | 166 | 0.030 |
Why?
|
Antibodies, Blocking | 1 | 1997 | 249 | 0.030 |
Why?
|
Sodium Channels | 1 | 1998 | 334 | 0.030 |
Why?
|
Webcasts as Topic | 1 | 2016 | 21 | 0.030 |
Why?
|
Quality-Adjusted Life Years | 1 | 2003 | 1737 | 0.030 |
Why?
|
Self Care | 1 | 2022 | 800 | 0.030 |
Why?
|
Umbilical Veins | 1 | 1997 | 421 | 0.030 |
Why?
|
Thiolester Hydrolases | 1 | 1997 | 92 | 0.030 |
Why?
|
Chromogranins | 1 | 1997 | 161 | 0.030 |
Why?
|
Lymphocyte Subsets | 1 | 1997 | 315 | 0.030 |
Why?
|
Viscosity | 3 | 1994 | 334 | 0.030 |
Why?
|
Thymectomy | 1 | 1997 | 200 | 0.030 |
Why?
|
Proliferating Cell Nuclear Antigen | 1 | 1997 | 284 | 0.030 |
Why?
|
Baculoviridae | 1 | 1996 | 115 | 0.030 |
Why?
|
Bronchoscopes | 1 | 1996 | 61 | 0.030 |
Why?
|
Administration, Topical | 2 | 1996 | 704 | 0.030 |
Why?
|
Parasympathomimetics | 1 | 1995 | 28 | 0.030 |
Why?
|
Oligonucleotide Probes | 1 | 1996 | 417 | 0.030 |
Why?
|
Steroids | 2 | 1998 | 933 | 0.030 |
Why?
|
India | 1 | 2002 | 2334 | 0.030 |
Why?
|
Artifacts | 1 | 2004 | 1893 | 0.030 |
Why?
|
Trust | 1 | 2000 | 533 | 0.030 |
Why?
|
Altitude Sickness | 1 | 1996 | 93 | 0.030 |
Why?
|
Drug Delivery Systems | 1 | 2007 | 2207 | 0.030 |
Why?
|
Fibrosis | 1 | 2003 | 2070 | 0.030 |
Why?
|
Severity of Illness Index | 7 | 2015 | 15880 | 0.030 |
Why?
|
Cell Division | 2 | 2001 | 4475 | 0.030 |
Why?
|
Receptors, Transforming Growth Factor beta | 1 | 1997 | 306 | 0.030 |
Why?
|
Protein Binding | 3 | 2003 | 9296 | 0.030 |
Why?
|
Altitude | 1 | 1996 | 162 | 0.030 |
Why?
|
Fatty Acids, Unsaturated | 4 | 1986 | 538 | 0.030 |
Why?
|
Drosophila | 2 | 2000 | 1501 | 0.030 |
Why?
|
Bronchial Diseases | 2 | 1989 | 151 | 0.030 |
Why?
|
Lymphocyte Depletion | 1 | 1997 | 605 | 0.030 |
Why?
|
In Situ Hybridization | 1 | 1999 | 1886 | 0.030 |
Why?
|
Polysomnography | 1 | 2002 | 1859 | 0.030 |
Why?
|
Oils | 2 | 1985 | 54 | 0.030 |
Why?
|
Chymases | 1 | 1994 | 85 | 0.030 |
Why?
|
Platelet Aggregation Inhibitors | 1 | 2007 | 2770 | 0.030 |
Why?
|
Phylogeny | 2 | 2006 | 2832 | 0.030 |
Why?
|
Tumor Cells, Cultured | 3 | 1997 | 6113 | 0.030 |
Why?
|
Growth Substances | 1 | 1997 | 758 | 0.030 |
Why?
|
Autonomic Nervous System | 1 | 1980 | 706 | 0.030 |
Why?
|
Cell Membrane | 1 | 2004 | 3633 | 0.030 |
Why?
|
Norepinephrine | 2 | 1988 | 900 | 0.030 |
Why?
|
Dexamethasone | 2 | 2004 | 1963 | 0.030 |
Why?
|
Cohort Studies | 5 | 2003 | 41647 | 0.030 |
Why?
|
Fiber Optic Technology | 1 | 1996 | 284 | 0.030 |
Why?
|
Liver Function Tests | 1 | 1996 | 525 | 0.030 |
Why?
|
Intercellular Adhesion Molecule-1 | 1 | 1998 | 1132 | 0.030 |
Why?
|
Information Storage and Retrieval | 1 | 2020 | 834 | 0.030 |
Why?
|
DNA, Complementary | 3 | 2004 | 1984 | 0.030 |
Why?
|
Homeostasis | 3 | 1998 | 3336 | 0.030 |
Why?
|
Survival Rate | 1 | 2008 | 12795 | 0.030 |
Why?
|
Attention | 1 | 2004 | 2418 | 0.030 |
Why?
|
Ergolines | 1 | 1994 | 55 | 0.030 |
Why?
|
Blood Proteins | 2 | 2001 | 1188 | 0.030 |
Why?
|
Treatment Failure | 4 | 2001 | 2652 | 0.030 |
Why?
|
Hemodynamics | 2 | 2002 | 4183 | 0.030 |
Why?
|
Infection Control | 1 | 2021 | 983 | 0.030 |
Why?
|
Methylprednisolone | 1 | 1995 | 386 | 0.030 |
Why?
|
HeLa Cells | 1 | 2000 | 3067 | 0.030 |
Why?
|
Argon | 1 | 1993 | 36 | 0.030 |
Why?
|
Fluorides | 3 | 1981 | 134 | 0.030 |
Why?
|
Gene Library | 2 | 1993 | 1067 | 0.030 |
Why?
|
Breast Neoplasms | 1 | 2001 | 21056 | 0.030 |
Why?
|
Bombesin | 1 | 1993 | 35 | 0.030 |
Why?
|
Oxidation-Reduction | 1 | 1999 | 2218 | 0.030 |
Why?
|
Paclitaxel | 1 | 2001 | 1728 | 0.030 |
Why?
|
Nursing Homes | 1 | 2021 | 1084 | 0.030 |
Why?
|
Antigen-Antibody Complex | 2 | 1984 | 508 | 0.030 |
Why?
|
Body Composition | 1 | 2003 | 2439 | 0.030 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 1999 | 2505 | 0.030 |
Why?
|
Serotonin Antagonists | 1 | 1994 | 146 | 0.030 |
Why?
|
Gelsolin | 1 | 1994 | 189 | 0.030 |
Why?
|
Risk Factors | 6 | 2022 | 74836 | 0.030 |
Why?
|
Humidity | 2 | 1992 | 206 | 0.030 |
Why?
|
Poly A | 1 | 1993 | 180 | 0.030 |
Why?
|
Infant | 2 | 2022 | 36385 | 0.030 |
Why?
|
Ion Channels | 1 | 1998 | 1045 | 0.030 |
Why?
|
Trypsin Inhibitors | 1 | 1993 | 32 | 0.030 |
Why?
|
Adenosine Triphosphate | 1 | 1999 | 1999 | 0.030 |
Why?
|
Terbutaline | 2 | 1992 | 26 | 0.030 |
Why?
|
Transfection | 3 | 2002 | 5743 | 0.030 |
Why?
|
Iron | 2 | 1999 | 1816 | 0.030 |
Why?
|
Methods | 2 | 1986 | 1052 | 0.030 |
Why?
|
Hydrolysis | 1 | 1994 | 642 | 0.030 |
Why?
|
Arachidonate 15-Lipoxygenase | 1 | 1993 | 84 | 0.030 |
Why?
|
Biological Transport | 4 | 1985 | 2081 | 0.030 |
Why?
|
Serotonin Receptor Agonists | 1 | 1994 | 151 | 0.030 |
Why?
|
Leupeptins | 1 | 1993 | 112 | 0.030 |
Why?
|
Nasopharynx | 1 | 1996 | 419 | 0.030 |
Why?
|
Reproducibility of Results | 3 | 2008 | 20125 | 0.030 |
Why?
|
Antibody Formation | 1 | 1997 | 1391 | 0.030 |
Why?
|
Tetrazoles | 2 | 1989 | 920 | 0.030 |
Why?
|
Probability | 3 | 2003 | 2475 | 0.030 |
Why?
|
Microscopy, Electron | 1 | 1996 | 2548 | 0.030 |
Why?
|
Animals, Newborn | 1 | 1998 | 2669 | 0.030 |
Why?
|
Crohn Disease | 1 | 2005 | 2283 | 0.030 |
Why?
|
Acetazolamide | 1 | 1992 | 98 | 0.020 |
Why?
|
Ascitic Fluid | 2 | 1984 | 190 | 0.020 |
Why?
|
Recombination, Genetic | 1 | 1997 | 1525 | 0.020 |
Why?
|
Logistic Models | 3 | 2003 | 13266 | 0.020 |
Why?
|
Parasympathetic Nervous System | 3 | 1999 | 144 | 0.020 |
Why?
|
Furosemide | 1 | 1992 | 175 | 0.020 |
Why?
|
Residual Volume | 2 | 1983 | 40 | 0.020 |
Why?
|
Plasmids | 1 | 1997 | 2274 | 0.020 |
Why?
|
Injections, Intraperitoneal | 2 | 2000 | 413 | 0.020 |
Why?
|
Protein Processing, Post-Translational | 1 | 1999 | 1957 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-ets | 2 | 2002 | 312 | 0.020 |
Why?
|
Ileum | 5 | 1984 | 558 | 0.020 |
Why?
|
Leucine | 1 | 1993 | 546 | 0.020 |
Why?
|
Cardiac Surgical Procedures | 1 | 2006 | 3675 | 0.020 |
Why?
|
Child, Preschool | 4 | 2022 | 42500 | 0.020 |
Why?
|
Tracheotomy | 2 | 1985 | 174 | 0.020 |
Why?
|
Lymph Nodes | 1 | 2002 | 3454 | 0.020 |
Why?
|
Odds Ratio | 2 | 2000 | 9649 | 0.020 |
Why?
|
Immunity, Innate | 1 | 2003 | 3081 | 0.020 |
Why?
|
Macrophages, Alveolar | 1 | 1993 | 413 | 0.020 |
Why?
|
Lymphocytes | 1 | 1999 | 2599 | 0.020 |
Why?
|
Evaluation Studies as Topic | 1 | 1993 | 1600 | 0.020 |
Why?
|
Multiple Myeloma | 1 | 2009 | 5197 | 0.020 |
Why?
|
Disease Susceptibility | 1 | 1997 | 1789 | 0.020 |
Why?
|
Electrophoresis, Polyacrylamide Gel | 2 | 1990 | 1724 | 0.020 |
Why?
|
Polyethylenes | 1 | 1993 | 289 | 0.020 |
Why?
|
Prednisone | 1 | 1995 | 1565 | 0.020 |
Why?
|
Interleukin-1 | 3 | 2002 | 1243 | 0.020 |
Why?
|
Age of Onset | 3 | 2002 | 3343 | 0.020 |
Why?
|
MAP Kinase Kinase 2 | 1 | 2010 | 92 | 0.020 |
Why?
|
Technology | 1 | 2012 | 297 | 0.020 |
Why?
|
Gene Expression Profiling | 1 | 2006 | 9524 | 0.020 |
Why?
|
Sex Characteristics | 1 | 2000 | 2643 | 0.020 |
Why?
|
Cost-Benefit Analysis | 1 | 2003 | 5526 | 0.020 |
Why?
|
Kidney Neoplasms | 1 | 2007 | 4274 | 0.020 |
Why?
|
Incidence | 1 | 2008 | 21480 | 0.020 |
Why?
|
Substrate Specificity | 2 | 2006 | 1752 | 0.020 |
Why?
|
Mammals | 1 | 1995 | 1125 | 0.020 |
Why?
|
Drug Monitoring | 1 | 1996 | 962 | 0.020 |
Why?
|
Creatinine | 1 | 1995 | 1915 | 0.020 |
Why?
|
Dose-Response Relationship, Immunologic | 1 | 1990 | 355 | 0.020 |
Why?
|
Combined Modality Therapy | 1 | 2022 | 8529 | 0.020 |
Why?
|
Hydrocortisone | 3 | 2002 | 1827 | 0.020 |
Why?
|
Sex Factors | 3 | 2003 | 10602 | 0.020 |
Why?
|
Vaccination | 1 | 2002 | 3426 | 0.020 |
Why?
|
Burimamide | 2 | 1980 | 2 | 0.020 |
Why?
|
Metiamide | 2 | 1980 | 6 | 0.020 |
Why?
|
Heparin | 1 | 1997 | 1630 | 0.020 |
Why?
|
Mitogen-Activated Protein Kinase 3 | 1 | 2011 | 474 | 0.020 |
Why?
|
Cardiac Output | 1 | 1972 | 840 | 0.020 |
Why?
|
Patient Selection | 1 | 2001 | 4255 | 0.020 |
Why?
|
Peptidyl-Dipeptidase A | 1 | 1991 | 323 | 0.020 |
Why?
|
Developing Countries | 1 | 2002 | 2911 | 0.020 |
Why?
|
Antigens, Differentiation | 1 | 1992 | 919 | 0.020 |
Why?
|
False Positive Reactions | 2 | 2002 | 955 | 0.020 |
Why?
|
Spleen | 2 | 2011 | 2296 | 0.020 |
Why?
|
Permeability | 1 | 1991 | 726 | 0.020 |
Why?
|
Temperature | 2 | 1988 | 2226 | 0.020 |
Why?
|
Cell Adhesion | 1 | 2015 | 3089 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 3 | 2008 | 20660 | 0.020 |
Why?
|
Sleep | 1 | 2004 | 4812 | 0.020 |
Why?
|
MAP Kinase Kinase 1 | 1 | 2010 | 330 | 0.020 |
Why?
|
Respiratory Muscles | 1 | 1989 | 144 | 0.020 |
Why?
|
Patient Compliance | 1 | 1998 | 2692 | 0.020 |
Why?
|
Receptors, Complement | 1 | 1989 | 240 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-fos | 1 | 2011 | 576 | 0.020 |
Why?
|
Survival Analysis | 1 | 2001 | 10070 | 0.020 |
Why?
|
Adipokines | 1 | 2010 | 308 | 0.020 |
Why?
|
Desensitization, Immunologic | 1 | 1973 | 544 | 0.020 |
Why?
|
Prognosis | 2 | 2006 | 29921 | 0.020 |
Why?
|
Regression Analysis | 3 | 2004 | 6321 | 0.020 |
Why?
|
Tachyphylaxis | 1 | 1987 | 54 | 0.020 |
Why?
|
Antibody Specificity | 2 | 2000 | 1061 | 0.020 |
Why?
|
Neoplasm Proteins | 1 | 1999 | 3596 | 0.020 |
Why?
|
Glycopeptides | 1 | 1989 | 224 | 0.020 |
Why?
|
Chromosome Deletion | 1 | 1992 | 1385 | 0.020 |
Why?
|
Neurons | 2 | 2001 | 9524 | 0.020 |
Why?
|
Area Under Curve | 2 | 2001 | 1638 | 0.020 |
Why?
|
Electronics, Medical | 1 | 1987 | 70 | 0.020 |
Why?
|
Ethane | 1 | 1986 | 3 | 0.020 |
Why?
|
Quality of Life | 2 | 2001 | 13461 | 0.020 |
Why?
|
Pilot Projects | 1 | 2000 | 8733 | 0.020 |
Why?
|
Peptide Hydrolases | 1 | 1990 | 608 | 0.020 |
Why?
|
Dimethyl Sulfoxide | 1 | 1988 | 251 | 0.020 |
Why?
|
Calorimetry | 1 | 1986 | 132 | 0.020 |
Why?
|
Sulfur Hexafluoride | 2 | 1988 | 26 | 0.020 |
Why?
|
Physiology | 2 | 1984 | 112 | 0.020 |
Why?
|
Chloralose | 1 | 1986 | 14 | 0.020 |
Why?
|
Actins | 1 | 1994 | 2056 | 0.020 |
Why?
|
Postoperative Complications | 1 | 2009 | 15747 | 0.020 |
Why?
|
Milrinone | 1 | 1986 | 87 | 0.020 |
Why?
|
Forecasting | 1 | 2015 | 2936 | 0.020 |
Why?
|
Blood Platelets | 1 | 1997 | 2464 | 0.020 |
Why?
|
Complement C3 | 1 | 1988 | 424 | 0.020 |
Why?
|
Sulfur | 2 | 1976 | 158 | 0.020 |
Why?
|
Consensus | 1 | 2016 | 3202 | 0.020 |
Why?
|
Rats, Inbred Strains | 2 | 1984 | 2077 | 0.020 |
Why?
|
Barbiturates | 1 | 1986 | 113 | 0.020 |
Why?
|
Atmospheric Pressure | 1 | 1985 | 47 | 0.020 |
Why?
|
Peptides | 2 | 2006 | 4331 | 0.020 |
Why?
|
Vitamin D | 1 | 2019 | 3272 | 0.020 |
Why?
|
Young Adult | 1 | 2012 | 59886 | 0.020 |
Why?
|
Receptors, Growth Factor | 1 | 2006 | 324 | 0.020 |
Why?
|
Cell Degranulation | 2 | 1999 | 280 | 0.020 |
Why?
|
Therapeutic Irrigation | 1 | 1986 | 297 | 0.020 |
Why?
|
Tyrphostins | 1 | 2005 | 63 | 0.020 |
Why?
|
Meta-Analysis as Topic | 1 | 2010 | 1370 | 0.020 |
Why?
|
Predictive Value of Tests | 4 | 2002 | 15398 | 0.020 |
Why?
|
Mice, Congenic | 1 | 2005 | 98 | 0.020 |
Why?
|
Premedication | 1 | 1985 | 244 | 0.010 |
Why?
|
Mouth Mucosa | 1 | 1987 | 432 | 0.010 |
Why?
|
Chemotaxis, Leukocyte | 3 | 2000 | 657 | 0.010 |
Why?
|
Metered Dose Inhalers | 1 | 2004 | 28 | 0.010 |
Why?
|
Lung Neoplasms | 2 | 2008 | 13451 | 0.010 |
Why?
|
Chi-Square Distribution | 2 | 2002 | 3432 | 0.010 |
Why?
|
Wounds and Injuries | 1 | 2017 | 2511 | 0.010 |
Why?
|
Disease Progression | 1 | 2022 | 13631 | 0.010 |
Why?
|
Antigens, Neoplasm | 1 | 1992 | 2002 | 0.010 |
Why?
|
Administration, Intranasal | 1 | 1986 | 482 | 0.010 |
Why?
|
Receptors, Aryl Hydrocarbon | 1 | 2006 | 222 | 0.010 |
Why?
|
Atlantic Islands | 1 | 2003 | 3 | 0.010 |
Why?
|
Tubocurarine | 1 | 1983 | 62 | 0.010 |
Why?
|
Placenta | 1 | 1993 | 1728 | 0.010 |
Why?
|
Drug Resistance | 1 | 1990 | 1591 | 0.010 |
Why?
|
Oxygen Consumption | 2 | 1984 | 1870 | 0.010 |
Why?
|
Uteroglobin | 1 | 2004 | 55 | 0.010 |
Why?
|
Histidine | 1 | 2004 | 301 | 0.010 |
Why?
|
Nuclear Proteins | 1 | 1998 | 5783 | 0.010 |
Why?
|
Thromboxanes | 1 | 1983 | 45 | 0.010 |
Why?
|
Acid-Base Equilibrium | 1 | 1984 | 180 | 0.010 |
Why?
|
Leukotriene D4 | 1 | 2003 | 33 | 0.010 |
Why?
|
Body Mass Index | 1 | 2001 | 13039 | 0.010 |
Why?
|
ROC Curve | 2 | 2002 | 3620 | 0.010 |
Why?
|
STAT6 Transcription Factor | 1 | 2004 | 197 | 0.010 |
Why?
|
Prevalence | 3 | 2010 | 15839 | 0.010 |
Why?
|
Epitopes | 1 | 1990 | 2523 | 0.010 |
Why?
|
Drug Synergism | 2 | 1988 | 1749 | 0.010 |
Why?
|
Atenolol | 1 | 1983 | 99 | 0.010 |
Why?
|
Puerto Rico | 1 | 2004 | 381 | 0.010 |
Why?
|
Tetracycline | 1 | 2004 | 216 | 0.010 |
Why?
|
Mice, SCID | 2 | 2002 | 2630 | 0.010 |
Why?
|
Patient Care | 1 | 2009 | 629 | 0.010 |
Why?
|
Founder Effect | 1 | 2003 | 185 | 0.010 |
Why?
|
Matrix Metalloproteinase 1 | 1 | 2002 | 147 | 0.010 |
Why?
|
Nitric Oxide Synthase Type II | 1 | 2004 | 512 | 0.010 |
Why?
|
Mexico | 1 | 2004 | 777 | 0.010 |
Why?
|
Diffusion | 1 | 1984 | 808 | 0.010 |
Why?
|
Binding Sites | 2 | 2003 | 6001 | 0.010 |
Why?
|
Dinoprost | 1 | 1982 | 139 | 0.010 |
Why?
|
Drug Evaluation, Preclinical | 1 | 1987 | 1333 | 0.010 |
Why?
|
Doxycycline | 1 | 2004 | 349 | 0.010 |
Why?
|
Stroke | 1 | 2004 | 9747 | 0.010 |
Why?
|
Collagen Type III | 1 | 2002 | 92 | 0.010 |
Why?
|
Partial Pressure | 1 | 1981 | 245 | 0.010 |
Why?
|
Glutamine | 1 | 2004 | 576 | 0.010 |
Why?
|
Nuclear Family | 1 | 2002 | 311 | 0.010 |
Why?
|
Mutagenesis, Site-Directed | 1 | 2004 | 1679 | 0.010 |
Why?
|
Biological Assay | 2 | 1981 | 627 | 0.010 |
Why?
|
Software | 1 | 2015 | 4462 | 0.010 |
Why?
|
Eosinophil Peroxidase | 1 | 2000 | 22 | 0.010 |
Why?
|
3T3 Cells | 1 | 2002 | 1081 | 0.010 |
Why?
|
Bucladesine | 1 | 2000 | 117 | 0.010 |
Why?
|
Intradermal Tests | 1 | 1980 | 43 | 0.010 |
Why?
|
Ethanol | 1 | 1987 | 1323 | 0.010 |
Why?
|
Graves Disease | 1 | 2002 | 241 | 0.010 |
Why?
|
Denervation | 2 | 1978 | 265 | 0.010 |
Why?
|
Piperazines | 1 | 2011 | 2549 | 0.010 |
Why?
|
Lipids | 3 | 2006 | 3316 | 0.010 |
Why?
|
Mice, Transgenic | 2 | 2004 | 9550 | 0.010 |
Why?
|
Transgenes | 1 | 2004 | 1015 | 0.010 |
Why?
|
Lidocaine | 1 | 1983 | 550 | 0.010 |
Why?
|
Hydroxydopamines | 1 | 1980 | 59 | 0.010 |
Why?
|
Adrenergic Fibers | 1 | 1980 | 21 | 0.010 |
Why?
|
Liver | 1 | 1996 | 7562 | 0.010 |
Why?
|
Densitometry | 1 | 2000 | 150 | 0.010 |
Why?
|
Membranes | 1 | 2000 | 164 | 0.010 |
Why?
|
Kidney | 1 | 1995 | 7066 | 0.010 |
Why?
|
Histamine Release | 2 | 1985 | 119 | 0.010 |
Why?
|
Finite Element Analysis | 1 | 2002 | 441 | 0.010 |
Why?
|
Anesthesia | 2 | 1982 | 1590 | 0.010 |
Why?
|
alpha 1-Antitrypsin | 1 | 2000 | 168 | 0.010 |
Why?
|
Nonlinear Dynamics | 1 | 2002 | 490 | 0.010 |
Why?
|
Compliance | 1 | 1979 | 100 | 0.010 |
Why?
|
Klebsiella Infections | 1 | 2001 | 146 | 0.010 |
Why?
|
Staining and Labeling | 1 | 2004 | 1072 | 0.010 |
Why?
|
Receptors, CCR2 | 1 | 2000 | 215 | 0.010 |
Why?
|
Histamine Antagonists | 1 | 1980 | 93 | 0.010 |
Why?
|
Fluorescent Antibody Technique | 1 | 2004 | 2476 | 0.010 |
Why?
|
Ventilators, Mechanical | 1 | 1981 | 291 | 0.010 |
Why?
|
Rheology | 1 | 1980 | 348 | 0.010 |
Why?
|
Phenethylamines | 1 | 1979 | 95 | 0.010 |
Why?
|
Rats, Inbred F344 | 1 | 2000 | 822 | 0.010 |
Why?
|
Klebsiella pneumoniae | 1 | 2001 | 253 | 0.010 |
Why?
|
Electricity | 1 | 1979 | 174 | 0.010 |
Why?
|
Histamine H2 Antagonists | 1 | 1980 | 168 | 0.010 |
Why?
|
Receptors, G-Protein-Coupled | 1 | 2006 | 1241 | 0.010 |
Why?
|
Food Hypersensitivity | 1 | 1987 | 737 | 0.010 |
Why?
|
Sequence Alignment | 1 | 2003 | 2171 | 0.010 |
Why?
|
Physical Stimulation | 1 | 2000 | 513 | 0.010 |
Why?
|
DNA Footprinting | 1 | 1998 | 97 | 0.010 |
Why?
|
Nucleic Acid Amplification Techniques | 1 | 2001 | 335 | 0.010 |
Why?
|
Methylhistamines | 1 | 1978 | 4 | 0.010 |
Why?
|
Maximal Voluntary Ventilation | 1 | 1998 | 14 | 0.010 |
Why?
|
Movement | 1 | 1985 | 1462 | 0.010 |
Why?
|
Quinazolines | 1 | 2005 | 1364 | 0.010 |
Why?
|
Recurrent Laryngeal Nerve | 1 | 1980 | 145 | 0.010 |
Why?
|
Phentolamine | 1 | 1978 | 102 | 0.010 |
Why?
|
Vasculitis | 1 | 2002 | 527 | 0.010 |
Why?
|
Endocarditis | 1 | 2002 | 350 | 0.010 |
Why?
|
Follow-Up Studies | 4 | 2002 | 39194 | 0.010 |
Why?
|
Multivariate Analysis | 2 | 2002 | 12057 | 0.010 |
Why?
|
Nose | 1 | 2002 | 519 | 0.010 |
Why?
|
Heart Failure | 1 | 2002 | 11840 | 0.010 |
Why?
|
Neck | 1 | 2002 | 733 | 0.010 |
Why?
|
Precipitin Tests | 1 | 1998 | 812 | 0.010 |
Why?
|
Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2000 | 452 | 0.010 |
Why?
|
Pseudomonas Infections | 1 | 2002 | 622 | 0.010 |
Why?
|
Chromogranin A | 1 | 1997 | 49 | 0.010 |
Why?
|
alpha 1-Antitrypsin Deficiency | 1 | 1998 | 113 | 0.010 |
Why?
|
Sodium Channel Blockers | 1 | 1998 | 170 | 0.010 |
Why?
|
Aquaporin 4 | 1 | 1998 | 161 | 0.010 |
Why?
|
Immunoglobulin G | 1 | 1989 | 4528 | 0.010 |
Why?
|
Protein Synthesis Inhibitors | 1 | 1997 | 187 | 0.010 |
Why?
|
Hydrogen-Ion Concentration | 1 | 1981 | 2477 | 0.010 |
Why?
|
Eye Diseases | 1 | 2002 | 659 | 0.010 |
Why?
|
Eicosapentaenoic Acid | 3 | 1986 | 565 | 0.010 |
Why?
|
Depression, Chemical | 1 | 1976 | 186 | 0.010 |
Why?
|
COS Cells | 1 | 1998 | 1136 | 0.010 |
Why?
|
Skin | 2 | 1980 | 4489 | 0.010 |
Why?
|
Genome | 1 | 2005 | 1753 | 0.010 |
Why?
|
Blotting, Western | 1 | 2004 | 5020 | 0.010 |
Why?
|
Quantitative Trait Loci | 1 | 2005 | 2140 | 0.010 |
Why?
|
Computers, Analog | 1 | 1976 | 6 | 0.010 |
Why?
|
Homozygote | 1 | 2001 | 1775 | 0.010 |
Why?
|
Genetic Markers | 1 | 2002 | 2601 | 0.010 |
Why?
|
Sequence Analysis | 1 | 1997 | 239 | 0.010 |
Why?
|
Zinc Fingers | 1 | 1998 | 576 | 0.010 |
Why?
|
Acetylcholine | 1 | 1978 | 626 | 0.010 |
Why?
|
Sex Distribution | 1 | 2001 | 2263 | 0.010 |
Why?
|
Adrenalectomy | 1 | 1978 | 344 | 0.010 |
Why?
|
Luminescent Measurements | 1 | 1997 | 341 | 0.010 |
Why?
|
Family Health | 1 | 2000 | 1253 | 0.010 |
Why?
|
Electronic Health Records | 1 | 2012 | 4873 | 0.010 |
Why?
|
Fever | 1 | 2002 | 1603 | 0.010 |
Why?
|
Protein Kinase Inhibitors | 1 | 2011 | 5696 | 0.010 |
Why?
|
Pharmacology | 1 | 1995 | 97 | 0.010 |
Why?
|
Cell Death | 1 | 2000 | 1679 | 0.010 |
Why?
|
Pseudomonas aeruginosa | 1 | 2002 | 1276 | 0.010 |
Why?
|
Headache | 1 | 2002 | 1259 | 0.010 |
Why?
|
Growth | 1 | 1996 | 365 | 0.010 |
Why?
|
Feedback | 1 | 1978 | 796 | 0.010 |
Why?
|
Rats, Wistar | 1 | 1998 | 1884 | 0.010 |
Why?
|
Radiography, Thoracic | 1 | 2000 | 1315 | 0.010 |
Why?
|
Tissue Distribution | 1 | 1998 | 2266 | 0.010 |
Why?
|
NADPH Dehydrogenase | 1 | 1993 | 43 | 0.010 |
Why?
|
Ubiquitin Thiolesterase | 1 | 1997 | 456 | 0.010 |
Why?
|
gamma-Globulins | 1 | 1993 | 119 | 0.010 |
Why?
|
Societies, Scientific | 1 | 1995 | 221 | 0.010 |
Why?
|
Linear Models | 1 | 2003 | 5876 | 0.010 |
Why?
|
Open Reading Frames | 1 | 1997 | 820 | 0.010 |
Why?
|
Pollen | 1 | 1973 | 79 | 0.010 |
Why?
|
Nitrous Oxide | 1 | 1994 | 166 | 0.010 |
Why?
|
Deoxyribonuclease I | 1 | 1994 | 228 | 0.010 |
Why?
|
Immune Sera | 1 | 1973 | 601 | 0.010 |
Why?
|
Thymidine | 1 | 1993 | 294 | 0.010 |
Why?
|
Guanylate Cyclase | 1 | 1994 | 205 | 0.010 |
Why?
|
Vitamin D-Binding Protein | 1 | 1994 | 129 | 0.010 |
Why?
|
Edetic Acid | 1 | 1973 | 274 | 0.010 |
Why?
|
Culture Techniques | 1 | 1973 | 515 | 0.010 |
Why?
|
S-Nitroso-N-Acetylpenicillamine | 1 | 1992 | 23 | 0.010 |
Why?
|
Neurons, Afferent | 1 | 1975 | 497 | 0.010 |
Why?
|
Penicillamine | 1 | 1992 | 59 | 0.010 |
Why?
|
Cyclic GMP | 1 | 1994 | 394 | 0.010 |
Why?
|
Indicator Dilution Techniques | 1 | 1972 | 43 | 0.010 |
Why?
|
Chemotactic Factors | 2 | 1984 | 195 | 0.010 |
Why?
|
Transcriptional Activation | 1 | 1998 | 1744 | 0.010 |
Why?
|
Electric Impedance | 1 | 1997 | 794 | 0.010 |
Why?
|
RNA Splicing | 1 | 1997 | 903 | 0.010 |
Why?
|
Chimera | 1 | 1993 | 455 | 0.010 |
Why?
|
Skin Physiological Phenomena | 1 | 1993 | 193 | 0.010 |
Why?
|
Sequence Homology, Amino Acid | 1 | 1996 | 2745 | 0.010 |
Why?
|
Phosphatidylcholines | 1 | 1993 | 403 | 0.010 |
Why?
|
Haplorhini | 1 | 1972 | 520 | 0.010 |
Why?
|
Monocytes | 1 | 1981 | 2595 | 0.010 |
Why?
|
Urine | 1 | 1992 | 360 | 0.010 |
Why?
|
Choline | 1 | 1993 | 510 | 0.010 |
Why?
|
Glutathione | 1 | 1993 | 588 | 0.010 |
Why?
|
Heart Rate | 2 | 1993 | 4203 | 0.010 |
Why?
|
Chemistry | 2 | 1981 | 325 | 0.010 |
Why?
|
Chemical Phenomena | 2 | 1981 | 483 | 0.010 |
Why?
|
Drug Tolerance | 1 | 1992 | 363 | 0.010 |
Why?
|
Brain | 1 | 1997 | 27178 | 0.010 |
Why?
|
Organ Size | 1 | 1975 | 2261 | 0.010 |
Why?
|
Sound | 1 | 1992 | 257 | 0.010 |
Why?
|
Immunoenzyme Techniques | 1 | 1993 | 1701 | 0.010 |
Why?
|
Emergency Medicine | 1 | 1999 | 1221 | 0.010 |
Why?
|
Models, Statistical | 1 | 2005 | 5089 | 0.010 |
Why?
|
Recombinant Fusion Proteins | 1 | 1998 | 3737 | 0.010 |
Why?
|
Life Style | 1 | 2001 | 3926 | 0.010 |
Why?
|
Oligonucleotides, Antisense | 1 | 1992 | 462 | 0.010 |
Why?
|
Cattle | 2 | 1986 | 3801 | 0.010 |
Why?
|
Chromatography, Agarose | 1 | 1989 | 29 | 0.010 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2002 | 4405 | 0.000 |
Why?
|
Complement C5 | 1 | 1989 | 99 | 0.000 |
Why?
|
Complement C5a | 1 | 1989 | 98 | 0.000 |
Why?
|
Receptor, Anaphylatoxin C5a | 1 | 1989 | 85 | 0.000 |
Why?
|
Peptide Mapping | 1 | 1989 | 259 | 0.000 |
Why?
|
Docosahexaenoic Acids | 2 | 1986 | 916 | 0.000 |
Why?
|
Swine | 2 | 1981 | 5988 | 0.000 |
Why?
|
Complement C3a | 1 | 1988 | 64 | 0.000 |
Why?
|
Chromatography, Affinity | 1 | 1989 | 521 | 0.000 |
Why?
|
Biophysical Phenomena | 1 | 1988 | 318 | 0.000 |
Why?
|
Hypotension | 1 | 1993 | 885 | 0.000 |
Why?
|
Biophysics | 1 | 1988 | 375 | 0.000 |
Why?
|
Stroke Volume | 1 | 1981 | 5596 | 0.000 |
Why?
|
Osteoporosis | 1 | 1996 | 1582 | 0.000 |
Why?
|
Boston | 1 | 1999 | 9338 | 0.000 |
Why?
|
Proportional Hazards Models | 1 | 2001 | 12509 | 0.000 |
Why?
|
Cell Differentiation | 1 | 2004 | 11640 | 0.000 |
Why?
|
Thromboxane B2 | 1 | 1986 | 143 | 0.000 |
Why?
|
DNA Replication | 1 | 1993 | 1433 | 0.000 |
Why?
|
Glycosylation | 1 | 1989 | 1100 | 0.000 |
Why?
|
Fetus | 1 | 1993 | 1878 | 0.000 |
Why?
|
Cineradiography | 1 | 1985 | 23 | 0.000 |
Why?
|
Arachidonate Lipoxygenases | 1 | 1985 | 16 | 0.000 |
Why?
|
Bronchography | 1 | 1985 | 70 | 0.000 |
Why?
|
Chemical Fractionation | 1 | 1985 | 60 | 0.000 |
Why?
|
Centrifugation, Density Gradient | 1 | 1985 | 297 | 0.000 |
Why?
|
Macaca mulatta | 2 | 1982 | 2341 | 0.000 |
Why?
|
Prospective Studies | 2 | 2002 | 54806 | 0.000 |
Why?
|
Glycosaminoglycans | 1 | 1988 | 606 | 0.000 |
Why?
|
Phospholipids | 1 | 1988 | 776 | 0.000 |
Why?
|
Fats | 1 | 1984 | 99 | 0.000 |
Why?
|
Clotrimazole | 1 | 1983 | 77 | 0.000 |
Why?
|
Carbohydrates | 1 | 1985 | 386 | 0.000 |
Why?
|
Models, Chemical | 1 | 1985 | 608 | 0.000 |
Why?
|
Rats, Sprague-Dawley | 1 | 1993 | 8102 | 0.000 |
Why?
|
Retrospective Studies | 2 | 2001 | 81515 | 0.000 |
Why?
|
Proteoglycans | 1 | 1985 | 793 | 0.000 |
Why?
|
Fishes | 1 | 1985 | 606 | 0.000 |
Why?
|
Spasm | 1 | 1981 | 131 | 0.000 |
Why?
|
Interleukin-8 | 1 | 1984 | 700 | 0.000 |
Why?
|
Protein Conformation | 1 | 1989 | 3946 | 0.000 |
Why?
|
Macaca fascicularis | 1 | 1982 | 907 | 0.000 |
Why?
|
Skin Tests | 1 | 1981 | 630 | 0.000 |
Why?
|
Muscle Tonus | 1 | 1978 | 82 | 0.000 |
Why?
|
Adenocarcinoma | 1 | 1994 | 6364 | 0.000 |
Why?
|
Fatty Acids | 1 | 1984 | 1806 | 0.000 |
Why?
|